New compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same
By designing oxadiazole derivative compounds, selective inhibition of HDAC6 was achieved, solving the problems of side effects and low bioavailability of existing HDAC inhibitors, and providing an effective treatment option for diseases related to HDAC6 activity.
Patent Information
- Application Number
- CN202180053894.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-09-02
- Filing Date
- 2021-09-01
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2041-09-01
AI Technical Summary
Existing non-selective HDAC inhibitors can cause side effects such as fatigue and nausea at high doses, limiting their drug development in areas other than anticancer agents. Furthermore, oxime derivatives and benzamide compounds suffer from low bioavailability and off-target activity. There is a need to develop new compounds with selective HDAC6 inhibitory activity to treat cancer, inflammatory diseases, autoimmune diseases, and neurological diseases.
A class of oxadiazole derivative compounds was developed, which, through specific chemical structure design, achieve selective inhibition of HDAC6, avoid inhibition of other HDAC classes, improve bioavailability and reduce side effects.
This oxadiazole derivative compound exhibits significant selective HDAC6 inhibitory activity, which can effectively prevent or treat diseases related to HDAC6 activity, such as cancer, inflammatory diseases, autoimmune diseases, and neurological diseases, reduce side effects, and improve drug safety and therapeutic efficacy.
Smart Images

Figure CN116033899B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a novel compound having histone deacetylase 6 (HDAC6) inhibitory activity, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, use thereof for preparing therapeutic drugs, a pharmaceutical composition comprising the compound, a therapeutic method using the composition, and a preparation method thereof.
[0002] background
[0003] In cells, post-translational modifications such as acetylation serve as extremely important regulatory modules at the center of biological processes and are also strictly controlled by a variety of enzymes. As the core protein constituting chromatin, histones act in the form of axes, around which DNA is wound, and therefore contribute to DNA condensation. In addition, the balance between the acetylation and deacetylation of histones plays an extremely important role in gene expression.
[0004] As an enzyme for removing acetyl groups from lysine residues of histone proteins constituting chromatin, it is known that histone deacetylase (HDAC) is associated with gene silencing and induces cell cycle arrest, angiogenesis inhibition, immunomodulation, apoptosis, etc. (Hassig et al., Curr. Opin. Chem. Biol. 1997, 1, 300-308). In addition, it is reported that the inhibition of HDAC enzyme function induces cancer cell apoptosis by reducing the activity of cancer cell survival-related factors and activating cancer cell death-related factors in vivo (Warrell et al., J. Natl. Cancer Inst. 1998, 90, 1621-1625).
[0005] In humans, 18 HDACs are known and are divided into four classes based on homology to yeast HDACs. In this case, eleven HDACs that use zinc as a cofactor can be divided into three classes: class I (HDAC1, 2, 3, 8), class II (IIa: HDAC4, 5, 7, 9; IIb: HDAC6, 10) and class IV (HDAC11). In addition, seven class III HDACs (SIRT 1-7) use NAD+ instead of zinc as a cofactor (Bolden et al., Nat. Rev. Drug Discov. 2006, 5 (9), 769-784).
[0006] A variety of HDAC inhibitors are currently in the preclinical or clinical development stage, but so far only non-selective HDAC inhibitors are known to be anticancer agents. Vorinostat (SAHA) and romidepsin (FK228) have been approved as therapeutic agents for cutaneous T-cell lymphoma, and panobinostat (LBH-589) has been approved as a therapeutic agent for multiple myeloma. However, it is known that non-selective HDAC inhibitors generally produce side effects at high doses, such as fatigue, nausea, etc. (Piekarz et al., Pharmaceuticals 2010, 3, 2751-2767). It is reported that the side effects are caused by the inhibition of Class I HDAC. Due to the side effects, etc., non-selective HDAC inhibitors are limited in drug development in other fields except anticancer agents (Witt et al., Cancer Letters 277 (2009) 8.21).
[0007] Meanwhile, it has been reported that selective inhibition of class II HDAC will not show the toxicity that occurs when class I HDAC is inhibited. In the case of developing selective HDAC inhibitors, it will be possible to solve the side effects caused by non-selective inhibition of HDAC, such as toxicity, etc. Therefore, there is an opportunity to develop selective HDAC inhibitors as effective therapeutic agents for a variety of diseases (Matthias et al., Mol. Cell. Biol. 2008, 28, 1688-1701).
[0008] It is known that HDAC6 (a class IIb HDAC) is mainly present in the cytoplasm and contains tubulin, and is therefore involved in the deacetylation of various non-histone substrates (HSP90, cortical actin, etc.) (Yao et al., Mol. Cell 2005, 18, 601-607). HDAC6 has two catalytic domains, in which the zinc finger domain at the C-terminus can bind to ubiquitinated proteins. It is known that HDAC6 has a variety of non-histone proteins as substrates, and therefore plays an important role in various diseases, such as cancer, inflammatory diseases, autoimmune diseases, neurological diseases, neurodegenerative disorders, etc. (Santo et al., Blood 2012119: 2579-258; Vishwakarma et al., International Immunopharmacology 2013, 16, 72-78; Hu et al., J. Neurol. Sci. 2011, 304, 1-8).
[0009] The structural features common to various HDAC inhibitors are composed of a capping group, a linker group, and a zinc binding group (ZBG), as shown in the structure of Vorinostat below. Many researchers have conducted studies on the inhibitory activity and selectivity of enzymes through structural modifications of the capping group and the linker group. In addition to the above groups, the zinc binding group is known to play a more important role in enzyme inhibitory activity and selectivity (Wiest et al., J. Org. Chem. 2013 78: 5051-5065; Methot et al., Bioorg. Med. Chem. Lett. 2008, 18, 973-978).
[0010]
[0011] Most of the zinc binding groups are composed of hydroxamic acid or benzamide, in which hydroxamic acid derivatives exhibit strong HDAC inhibition, but have low bioavailability and serious off-target activity problems. Benzamide contains aniline and therefore has the problem of possibly producing toxic metabolites in vivo (Woster et al., Med. Chem. Commun. 2015, published online).
[0012] Therefore, unlike non-selective inhibitors with side effects, there is a need to develop selective HDAC6 inhibitors with zinc-binding groups that have improved bioavailability while not causing side effects for the treatment of cancer, inflammatory diseases, autoimmune diseases, neurological diseases, neurodegenerative disorders, etc.
[0013] [Prior art reference]
[0014] [Patent document]
[0015] International Patent Publication No. WO 2011 / 091213 (published on July 28, 2011): ACY-1215
[0016] International Patent Publication No. WO 2011 / 011186 (published on January 27, 2011): Tubastatin
[0017] International Patent Publication No. WO 2013 / 052110 (published on April 11, 2013): Sloan-K
[0018] International Patent Publication No. WO 2013 / 041407 (published on March 28, 2013): Cellzome
[0019] International Patent Publication No. WO 2013 / 134467 (published on September 12, 2013): Kozi
[0020] International Patent Publication No. WO 2013 / 008162 (published on January 17, 2013): Novartis
[0021] International Patent Publication No. WO 2013 / 080120 (published on June 6, 2013): Novartis
[0022] International Patent Publication No. WO 2013 / 066835 (published on May 10, 2013): Tempero
[0023] International Patent Publication No. WO 2013 / 066838 (published on May 10, 2013): Tempero
[0024] International Patent Publication No. WO 2013 / 066833 (published on May 10, 2013): Tempero
[0025] International Patent Publication No. WO 2013 / 066839 (published on May 10, 2013): Tempero DETAILED DESCRIPTION OF THE INVENTION
[0027] Technical issues
[0028] The object of the present invention is to provide a novel compound having selective HDAC6 inhibitory activity, a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
[0029] Another object of the present invention is to provide a pharmaceutical composition containing a novel compound having selective HDAC6 inhibitory activity, a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
[0030] Another object of the present invention is to provide a method for preparing the compound.
[0031] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating a disease related to HDAC6 activity, which contains a compound, a stereoisomer thereof or a pharmaceutically acceptable salt thereof as an active ingredient.
[0032] Another object of the present invention is to provide a compound, a stereoisomer thereof or a pharmaceutically acceptable salt thereof; or a pharmaceutical composition containing the same as an active ingredient for use in preventing or treating diseases related to HDAC6 activity.
[0033] Another object of the present invention is to provide a compound, a stereoisomer thereof or a pharmaceutically acceptable salt thereof; or a pharmaceutical composition containing the same as an active ingredient in the preparation of a drug for preventing or treating a disease related to HDAC6 activity.
[0034] Another object of the present invention is to provide a method for preventing or treating a disease related to HDAC6 activity, which comprises administering to an individual in need thereof a therapeutically effective amount of a compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; or a pharmaceutical composition containing the same as an active ingredient.
[0035] Technical Solution
[0036] The inventors have discovered oxadiazole derivative compounds having histone deacetylase 6 (HDAC6) inhibitory activity and have used them to inhibit or treat HDAC6 activity-related diseases, thereby completing the present invention.
[0037] The compound represented by chemical formula I
[0038] The present invention provides a novel compound having selective HDAC6 inhibitory activity represented by the following chemical formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
[0039] [Chemical Formula I]
[0040]
[0041] in,
[0042] Z1 to Z4 are each independently N or CR0 (wherein R0 is H or halogen);
[0043] R1 is CX3 or CX2H (wherein X is halogen);
[0044] for
[0045] R4 and R5 are each independently H or C1-C4 alkyl,
[0046] Z5 is N-R6 or CH2,
[0047] R6 is H, C1-C4 alkyl, -C(=O)-(C1-C4 alkyl), -C(=O)-O-(C1-C4 alkyl), or a 4- to 6-membered heterocycloalkyl group having one O;
[0048] L1 is -(C1-C2 alkylene)-;
[0049] is a C6-C12 aryl group, a 5- to 9-membered heteroaryl group having at least one N, or R2 and R3 are each independently H, halogen, C1-C4 alkyl, C6-C12 aryl, 5- or 6-membered heteroaryl having N or O, 5- or 6-membered heterocycloalkyl having N, 5- or 6-membered heterocycloalkenyl having N, -C(=O)-O-(C1-C4 alkyl), -C(=O)-(C1-C4 alkyl), -NH-C(=O)-(C1-C4 alkyl), -NO2 or -NH2,
[0050] At least one H in the above R2 and R3 may be independently substituted by halogen or C1-C4 alkyl; and
[0051] n and m are each independently 1 or 2.
[0052] In one embodiment, in the above Chemical Formula I,
[0053] R2 and R3 are each independently H, halogen, C1-C4 alkyl, phenyl, furanyl, pyridyl, C1-C4 alkyl substituted or unsubstituted piperidyl, C1-C4 alkyl substituted or unsubstituted tetrahydropyridyl, -C(=O)-O-(C1-C4 alkyl), -C(=O)-(C1-C4 alkyl), -NH-C(=O)-(C1-C4 alkyl), -NO2 or -NH2,
[0054] is phenyl, indole or
[0055] if Indole or The H of its NH can be replaced by -C(=O)-O-(C1-C4 alkyl) or -C(=O)-(C1-C4 alkyl), and if is phenyl, at least one H of the phenyl group may be independently substituted by halogen, and
[0056] n and m may each independently be 1 or 2.
[0057] In the present invention, the term "substituted" may refer to a moiety having a substituent replacing at least one hydrogen on a backbone carbon. "Substituted", "substitutable by" or "substituted by" may be defined to include implicit conditions, wherein the substitution follows the valence states allowed by the substituted atom and the substituent and induces a compound that is stable by substitution, for example, a compound that is not naturally modified by rearrangement, cyclization, removal, etc.
[0058] In the present invention, "Cx-y" may refer to a carbon atom having a range of x to v.
[0059] In the present invention, "alkyl" may refer to a linear (or straight-chain) saturated hydrocarbon group or a branched (or side-chain) saturated hydrocarbon group, and includes methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, etc.
[0060] In the present invention, "alkylene" may refer to a divalent functional group derived from an alkyl group as defined above.
[0061] In the present invention, "aryl" may include a monocyclic aromatic structure or a polycyclic aromatic structure, and a structure in which a saturated hydrocarbon ring is fused into a monocyclic or polycyclic aromatic group. Aryl may include phenyl, naphthyl, tetrahydronaphthyl, anthracenyl, phenanthrenyl, pyrenyl, etc.
[0062] In the present invention, "heteroaryl" may refer to a monocyclic or polycyclic heterocyclic ring in which at least one carbon atom is replaced by at least one heteroatom, wherein the heteroatom is at least one of nitrogen (N) and oxygen (O) in the aryl group as defined above. Heteroaryl may include pyridyl, triazolyl, tetrazolyl, indolyl, isoindolyl, furanyl, pyrrolyl, imidazolyl, oxazolyl, isoxazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, etc., but are not limited thereto.
[0063] In the present invention, "cycloalkyl" may refer to a saturated hydrocarbon ring generally having a specified number of carbon atoms containing the ring, and may include cyclohexyl, cycloheptyl, cyclooctyl, etc. In the present invention, "heterocycloalkyl" may refer to a saturated ring structure containing one to four heteroatoms, which are at least one of nitrogen (N) and oxygen (O).
[0064] In the present invention, the "heterocycloalkenyl group" may refer to a structure containing one to four heteroatoms having at least one carbon-carbon double bond, and the heteroatom is at least one of nitrogen (N) and oxygen (O).
[0065] In the present invention, "halogen" may refer to F, Cl or Br.
[0066] In the present invention, "stereoisomers" may include diastereomers and optical isomers (enantiomers), wherein the optical isomers may include not only enantiomers but also mixtures and even racemates of the enantiomers.
[0067] In the present invention, pharmaceutically acceptable salts may refer to salts commonly used in the pharmaceutical field, for example, inorganic ion salts prepared from calcium, potassium, sodium, magnesium, etc.; inorganic acid salts prepared from hydrochloric acid, nitric acid, phosphoric acid, bromic acid, iodic acid, perchloric acid, sulfuric acid, etc.; organic acid salts prepared from acetic acid, trifluoroacetic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid, hydroiodic acid, etc.; sulfonates prepared from methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, etc.; amino acid salts prepared from glycine, arginine, lysine, etc.; ammonium salts prepared from trimethylamine, triethylamine, ammonia, pyridine, picoline, etc.; etc., but the types of salts referred to in the present invention are not limited to these listed salts.
[0068] In the present invention, preferred salts may include hydrochloride, phosphate, sulfate, trifluoroacetate, citrate, bromate, maleate or tartrate.
[0069] In one embodiment, the compound represented by Chemical Formula I of the present invention, its stereoisomer or a pharmaceutically acceptable salt thereof may include compounds as shown in Table 1 below.
[0070] [Table 1]
[0071]
[0072]
[0073]
[0074] Method for preparing the compound represented by Chemical Formula I
[0075] The present invention may provide a method for preparing the compound represented by Chemical Formula I, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.
[0076] A preferred method for preparing the compound represented by Chemical Formula I, its stereoisomer or a pharmaceutically acceptable salt thereof is the same as shown in Reaction Formulas 1, 1-1 and 2 to 7, and even the preparation method modified at a level obvious to those skilled in the art is included therein.
[0077] In each of Reaction Formulas 1, 1-1, and 2 to 7, R1 to R5, Z1 to Z4, L1, m, n, and X are each substantially the same as defined in Chemical Formula 1. In Reaction Formulas 1, 1-1, and 2 to 7, "halo" may refer to a halogen of F, Cl, or Br. In addition, in Reaction Formulas 1, 1-1, and 2 to 7, "PG" may refer to a protecting group of a nitrogen atom and may include tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), and the like.
[0078] [Reaction 1]
[0079]
[0080] The above reaction formula 1 shows a method for synthesizing a compound having an imidazolidine-2,4-dione structure, wherein the compound of the chemical formula 1-1-1 can react with the compound of the chemical formula 1-1-2 and the compound of the chemical formula 1-1-3 to prepare the compound of the chemical formula 1-1-4 having an aminonitrile structure. Thereafter, the resulting compound can react with the compound of the chemical formula 1-1-5 to prepare the compound of the chemical formula 1-1-6 having an imidazolidine-2,4-dione structure, and then react with the compound of the chemical formula 1-1-7 to prepare the compound of the chemical formula 1-1-8.
[0081] In the present invention, the compound prepared according to the above reaction formula 1 may include 3, 4, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, etc.
[0082] [Reaction formula 1-1]
[0083]
[0084] The above reaction formula 1-1 refers to a chemical reaction substantially the same as the above reaction formula 1, wherein the compound of chemical formula 1-1-1 can react with the compound of chemical formula 1-2-1a and the compound of chemical formula 1-1-3 to prepare the compound of chemical formula 1-2-2a. Thereafter, the resulting compound can react with the compound of chemical formula 1-1-5 to prepare the compound of chemical formula 1-2- having an imidazolidine-2,4-dione structure, and then react with the compound of chemical formula 1-1-7 to prepare the compound of chemical formula 1-2-4a. In the present invention, the compound prepared according to the above reaction formula 1-1 may include 24, etc.
[0085] [Reaction 2]
[0086]
[0087] In the above reaction formula 2, "R x" may represent a C1-C4 alkyl group, a 4- to 6-membered heterocycloalkyl group having one O, or a C(=O)-(C1-C4 alkyl group). Reaction Formula 2 above shows a method for synthesizing a compound having an imidazolidine-2,4-dione structure, wherein the compound of Chemical Formula 1-1-1 may be reacted with a compound of Chemical Formula 1-2-1 to which a protecting group is added, and a compound of Chemical Formula 1-1-3 to prepare a compound of Chemical Formula 1-2-2 having an aminonitrile structure. Thereafter, the resulting compound may be reacted with a compound of Chemical Formula 1-1-5 to prepare a compound of Chemical Formula 1-2-3 having an imidazolidine-2,4-dione structure, and then reacted with a compound of Chemical Formula 1-1-7 to prepare a compound of Chemical Formula 1-2-4. The protecting group may be removed from the compound of Chemical Formula 1-2-4 to prepare a compound of Chemical Formula 1-2-5, and then a reductive amination reaction or a substitution reaction may be performed to prepare a compound of Chemical Formula 1-2-6.
[0088] In the present invention, the compound prepared according to the above reaction formula 2 may include 5, 6, 7, 8, 21, 22, 23, etc.
[0089] [Reaction 3]
[0090]
[0091] The above reaction formula 3 shows a method for synthesizing a compound having an imidazolidine-2,4-dione structure, wherein the compound of Chemical Formula 1-3-1 prepared in Reaction Formula 1 can be subjected to CC coupling (Suzuki reaction) with the compound of Chemical Formula 1-3-2 to prepare the compound of Chemical Formula 1-3-3.
[0092] In the present invention, the compound prepared according to the above reaction formula 3 may include 25, 26, 27, 28, 29, etc.
[0093] [Reaction 4]
[0094]
[0095] In the above reaction formula 4, "R a " may be C(=O)-(C1-C4 alkyl).
[0096] The above reaction formula 4 shows a method for synthesizing a compound having an imidazolidine-2,4-dione structure, wherein the protecting group can be removed from the compound of the chemical formula 1-4-1 having a protecting group prepared in the reaction formula 1 to prepare the compound of the chemical formula 1-4-2, and then a reduction reaction can be performed to prepare the compound of the chemical formula 1-4-3. Thereafter, a reductive amination reaction or a substitution reaction can be performed to prepare the compound of the chemical formula 1-4-4.
[0097] In the present invention, the compound prepared according to the above reaction formula 4 may include 30, 31, 32, 33, 37, etc.
[0098] [Reaction 5]
[0099]
[0100] In the above reaction formula 5, "R b " may be -C(=O)-(C1-C4 alkyl).
[0101] The above reaction formula 5 shows a method for synthesizing a compound having an imidazolidine-2,4-dione structure, wherein the compound of the chemical formula 1-5-1 to which a nitro group is added prepared in reaction formula 1 can be subjected to a reduction reaction to prepare a compound of the chemical formula 1-5-2, and then a reductive amination reaction or a substitution reaction can be performed to prepare a compound of the chemical formula 1-5-3.
[0102] In the present invention, the compound prepared according to the above reaction formula 5 may include 34, 35, 36, etc.
[0103] [Reaction 6]
[0104]
[0105] In the above reaction formula 6, R c It can be a C1-C4 alkyl group.
[0106] The above reaction formula 6 shows a method for synthesizing a compound having an imidazolidine-2,4-dione structure, wherein the compound of the chemical formula 1-3-1 prepared in reaction formula 1 can be subjected to CC coupling (Suzuki reaction) with the compound of the chemical formula 1-6-1 having a protecting group to prepare the compound of the chemical formula 1-6-2. The protecting group can be removed from the compound of the chemical formula 1-6-2 to prepare the compound of the chemical formula 1-6-3, and then a reductive amination reaction or a substitution reaction can be performed to prepare the compound of the chemical formula 1-6-4. Thereafter, a reduction reaction can be performed to prepare the compound of the chemical formula 1-6-5.
[0107] In the present invention, the compound prepared according to the above reaction formula 6 may include 19, 20, etc.
[0108] [Reaction 7]
[0109]
[0110] In the above reaction formula 7, the alkyl group may be a C1-C4 alkyl group.
[0111] The above reaction formula 7 shows a method for synthesizing a compound having an imidazolidine-2,4-dione structure, wherein the compound of the chemical formula 1-7-1 can react with the compound of the chemical formula 1-7-2 to prepare the compound of the chemical formula 1-7-3, and a cyclization reaction can be performed to prepare the compound of the chemical formula 1-7-4. The compound of the chemical formula 1-7-6 can be prepared by a substitution reaction between the compound of the chemical formula 1-7-4 and the compound of the chemical formula 1-7-5, and then the compound of the chemical formula 1-7-6 can react with hydrazine to prepare the compound of the chemical formula 1-7-7, and then react with difluoroacetic anhydride and trifluoroacetic anhydride to prepare the compound of the chemical formula 1-7-8. Thereafter, the compound of the chemical formula 1-7-8 can be subjected to a cyclization reaction with a Burgess reagent to prepare the compound of the chemical formula 1-7-9.
[0112] In the present invention, the compound prepared according to the above reaction formula 7 may include 1, 2, etc.
[0113] Compositions containing compounds represented by chemical formula I, uses thereof, and methods of treatment using the same
[0114] The present invention can provide a pharmaceutical composition for preventing or treating a disease mediated by histone deacetylase (HDAC), which contains a compound represented by the above chemical formula I, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. Preferably, the present invention can provide a pharmaceutical composition for preventing or treating a disease related to HDAC6 activity. The above chemical formula I is the same as defined above.
[0115] The pharmaceutical composition of the present invention can selectively inhibit HDAC6, thereby showing a significant effect on preventing or treating diseases related to histone deacetylase 6 activity.
[0116] Histone deacetylase (HDAC)-mediated diseases (particularly HDAC6 activity-related diseases) may include infectious diseases, such as prion diseases; tumors, such as benign tumors (e.g., myelodysplastic syndrome) or malignant tumors (e.g., multiple myeloma, lymphoma, leukemia, lung cancer, colorectal cancer, colon cancer, prostate cancer, urothelial carcinoma, breast cancer, melanoma, skin cancer, liver cancer, brain cancer, gastric cancer, ovarian cancer, pancreatic cancer, head and neck cancer, oral cancer or glioma); endocrine diseases, nutritional and metabolic diseases, such as hepatolenticular degeneration, amyloidosis or diabetes; mental and behavioral disorders, such as depression or Rett syndrome; neurological diseases, such as central nervous system atrophy (e.g., Huntington's disease, spinal muscular atrophy (SMA), spinocerebellar ataxia (SCA)), neurodegenerative diseases (e.g., Alzheimer's disease), movement disorders (e.g., Parkinson's disease), neurological diseases (e.g., , hereditary neuropathy (Charlottey-Marseille-Tooth disease), sporadic neuropathy, inflammatory neuropathy, drug-induced neuropathy), motor neuropathy (e.g., amyotrophic lateral sclerosis (ALS)), central nervous system demyelinating diseases (e.g., multiple sclerosis (MS)), etc.; eye and eye adnexal diseases, such as uveitis; circulatory system diseases, such as atrial fibrillation, stroke, etc.; respiratory system diseases, such as asthma; digestive diseases, such as alcoholic liver disease, inflammatory bowel disease, Crohn's disease, ulcerative bowel disease, etc.; skin and subcutaneous tissue diseases, such as psoriasis; musculoskeletal system and connective tissue diseases, such as rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus (SLE), etc.; or teratosis, deformity and chromosomal aberration, such as autosomal dominant polycystic kidney disease, and may also include other symptoms or diseases associated with abnormal histone deacetylase function.
[0117] The pharmaceutically acceptable salts are the same as described in the pharmaceutically acceptable salts of the compounds of the present invention.
[0118] Regarding administration, in addition to the compound, its stereoisomer or its pharmaceutically acceptable salt, the pharmaceutical composition of the present invention may further contain at least one type of pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier used may include a mixture of physiological saline, sterile water, Ringer's solution, buffered saline, glucose solution, maltodextrin solution, glycerol, ethanol and at least one component thereof, and other conventional additives may be added thereto as needed, such as antioxidants, buffer solutions, antibacterial agents, etc. In addition, diluents, dispersants, surfactants, adhesives and lubricants may be added to be formulated into injectable dosage forms, such as aqueous solutions, suspensions, emulsions, etc., pills, capsules, granules or tablets. Therefore, the composition of the present invention may be a patch, a liquid, a pill, a capsule, a granule, a tablet, a suppository, etc. Such preparations may be prepared according to the conventional methods used in the art or the methods disclosed in Remington's Pharmaceutical Science (latest edition), Mack Publishing Company, Easton PA, and such compositions may be formulated into various preparations according to each disease or component.
[0119] The composition of the present invention can be orally or parenterally administered (e.g., intravenously, subcutaneously, intraperitoneally or topically) according to a targeted method, wherein the dosage varies according to the patient's weight, age, sex, health condition and diet, administration time, administration method, excretion rate, severity of the disease, etc. The daily dosage of the compound of the present invention, its stereoisomer or a pharmaceutically acceptable salt thereof may be about 1 to 1000 mg / kg, preferably 5 to 100 mg / kg, and may be administered once a day or several times a day by dividing the daily dosage of the compound.
[0120] In addition to the compound, its stereoisomer or a pharmaceutically acceptable salt thereof, the pharmaceutical composition of the present invention may further contain at least one effective ingredient which exhibits the same or similar pharmaceutical effects.
[0121] The present invention can provide a method for preventing or treating a disease mediated by histone deacetylase (HDAC), comprising administering to an individual in need thereof a therapeutically effective amount of a compound represented by the above chemical formula I, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; or a pharmaceutical composition containing the same as an active ingredient. The disease mediated by histone deacetylase (HDAC) can be a disease associated with HDAC6 activity.
[0122] As used herein, the term "therapeutically effective amount" may refer to an amount of a compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof that is effective for preventing or treating a histone deacetylase (HDAC)-mediated disease, particularly a HDAC6 activity-related disease.
[0123] In the present invention, the term "subject" may refer to mammals including humans, and the term "administration" may refer to providing a predetermined substance to an individual by any appropriate method. It is obvious to those skilled in the art that the therapeutically effective dose and the number of administrations of the active ingredient of the present invention may vary according to the desired effect.
[0124] In the present invention, the term "prevention" may refer to delaying the occurrence of a disease, disorder or condition. If the occurrence of a disease, disorder or condition is delayed for an expected period of time, the prevention may be considered complete.
[0125] In the present invention, the term "treat" may refer to partially or completely reducing, ameliorating, alleviating, inhibiting or delaying the occurrence of a disease, disorder and / or condition, reducing its severity or reducing the occurrence of at least one symptom or property thereof.
[0126] In addition, the present invention can provide a method for selectively inhibiting HDAC6 by administering a therapeutically effective amount of a compound represented by the above chemical formula I, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; or a pharmaceutical composition containing the same as an active ingredient to mammals including humans.
[0127] The method for preventing or treating a disease mediated by histone deacetylase (HDAC) (specifically a disease related to HDAC6 activity) according to the present invention may include not only treating the disease itself before the symptoms are manifested by administering a compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, but also suppressing or avoiding such symptoms. When controlling the disease, the preventive or therapeutic dose of a certain active ingredient may vary according to the nature and severity of the disease or condition and the route of administering the active component. The dose and its frequency may vary according to the age, weight, and response of individual patients. Suitable doses and usage may be easily selected by those skilled in the art, naturally taking such factors into account. In addition, the method for preventing or treating a disease mediated by histone deacetylase (HDAC) (specifically a disease related to HDAC6 activity) according to the present invention may further include administering a therapeutically effective amount of another active agent that helps treat the disease, together with the compound represented by the above chemical formula I, and the other active agent may show a synergistic effect or an additive effect together with the compound, its stereoisomer, or a pharmaceutically acceptable salt thereof.
[0128] The present invention may also provide a compound represented by chemical formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof; or a pharmaceutical composition containing the same as an active ingredient for preventing or treating a disease mediated by histone deacetylase (HDAC). The disease mediated by histone deacetylase (HDAC) may be a disease related to HDAC6 activity.
[0129] The present invention can also provide a compound represented by the above chemical formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof; or a pharmaceutical composition containing the same as an active ingredient in the preparation of a drug for preventing or treating a disease mediated by histone deacetylase (HDAC). The disease mediated by histone deacetylase (HDAC) can be a disease related to HDAC6 activity.
[0130] To prepare drugs, the compound, its stereoisomer or pharmaceutically acceptable salt thereof can be combined with acceptable adjuvants, diluents, carriers, etc., and can be prepared into a complex preparation together with other active agents and thus have a synergistic effect of the active ingredients.
[0131] Matters mentioned in the uses, compositions and methods of treatment of the present invention are equally applicable unless they are contradictory to each other.
[0132] Beneficial Effects
[0133] According to the present invention, the compound represented by the above chemical formula I, its stereoisomer or a pharmaceutically acceptable salt thereof not only has HDAC6 inhibitory activity, but also has a remarkable excellent effect of preventing or treating HDAC6 activity-related diseases by selectively inhibiting HDAC6.
[0134] Furthermore, the compounds of the present invention, stereoisomers thereof or pharmaceutically acceptable salts thereof having selective HDAC6 inhibitory activity can be advantageously used to prevent or treat HDAC6 activity-related diseases, such as cancer, inflammatory diseases, autoimmune diseases, neurological diseases or neurodegenerative disorders, and the like.
[0135] The best way to invent
[0136] Hereinafter, the present invention will be described in more detail by the following examples and experimental examples. However, these examples are provided only for the purpose of illustrating the present invention, and therefore the scope of the present invention is not limited thereto.
[0137] Preparation of compounds
[0138] The specific method for preparing the compound represented by Chemical Formula I is the same as below.
[0139] Example 1: Synthesis of Compound 1, 1-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-5,5-dimethyl-3-phenylimidazolidine-2,4-dione
[0140] [Step 1] Synthesis of N′-(2,2-difluoroacetyl)-4-((5,5-dimethyl-2,4-dioxo-3-phenylimidazolidin-1-yl)methyl)-3-fluorobenzohydrazide
[0141]
[0142] 4-((5,5-dimethyl-2,4-dioxo-3-phenylimidazolidin-1-yl)methyl)-3-fluorobenzohydrazide (0.119 g, 0.321 mmol) and triethylamine (0.067 mL, 0.482 mmol) were dissolved in dichloromethane (4 mL) at room temperature, and then 2,2-difluoroacetic anhydride (0.036 mL, 0.289 mmol) was added to the resulting solution and stirred at the same temperature. The solvent was removed from the reaction mixture under reduced pressure, and the resulting concentrate was purified by column chromatography (SiO2, 4 g cartridge; ethyl acetate / hexane=20 to 70%) and concentrated to obtain the title compound (0.053 g, 36.8%) as a colorless oil.
[0143] [Step 2] Synthesis of Compound 1
[0144]
[0145] N'-(2,2-difluoroacetyl)-4-((5,5-dimethyl-2,4-dioxo-3-phenylimidazolidin-1-yl)methyl)-3-fluorobenzohydrazide (0.053 g, 0.118 mmol) prepared in step 1 and 1-methoxy-N-triethylaminosulfonyl-methan imidate (Burgess reagent, 0.042 g, 0.177 mmol) were mixed in tetrahydrofuran (4 mL) at room temperature, and the resulting mixture was irradiated with microwaves, and then heated at 150°C for 30 minutes, and then the reaction was completed by lowering the temperature to room temperature. The solvent was removed from the reaction mixture under reduced pressure, and water was poured into the resulting concentrate, which was then extracted with ethyl acetate. The organic layer was washed with a saturated aqueous bicarbonate solution, dehydrated with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 4 g cartridge; ethyl acetate / hexane = 0 to 40%) and concentrated to afford the title compound (0.009 g, 17.7%) as a colorless oil.
[0146] 1 H NMR (400MHz, CDCl3) δ7.94 (d, J=8.2Hz, 1H), 7.88 (d, J=10.0Hz, 1H), 7.53~7.4 7(m, 4H), 7.43~7.39(m, 1H), 6.95(t, J=51.6Hz, 1H), 4.77(s, 2H); LRMS(ES)m / z 431.0(M + +1).
[0147] Synthesis of Compound 2,1-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-5,5-dimethyl-3-phenylimidazolidine-2,4-dione
[0148] [Step 1] Synthesis of methyl 2-methyl-2-(3-phenylureido)propionate
[0149]
[0150] Isocyanatobenzene (1.000 g, 8.395 mmol), methyl 2-amino-2-methylpropanoate (1.418 g, 9.234 mmol) and triethylamine (1.280 mL, 9.234 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and the resulting solution was stirred at the same temperature for 8 hours. The solvent was removed from the reaction mixture under reduced pressure, and the resulting product was used without further purification (1.900 g, 95.8%, white solid).
[0151] [Step 2] Synthesis of 5,5-dimethyl-3-phenylimidazolidine-2,4-dione
[0152]
[0153] The methyl 2-methyl-2-(3-phenylureido)propanoate (1.900 g, 8.028 mmol) prepared in step 1 and 4 M aqueous hydrochloric acid solution (4.00 M solution in dioxane, 8.028 mL, 32.112 mmol) were dissolved in methanol (20 mL) at room temperature, and the resulting solution was stirred at the same temperature for 12 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dehydrated with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified and concentrated by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane = 0 to 30%) to obtain the desired title compound (1.300 g, 79.3%) as a white solid.
[0154] [Step 3] Synthesis of methyl 4-((5,5-dimethyl-2,4-dioxo-3-phenylimidazolidin-1-yl)methyl)-3-fluorobenzoate
[0155]
[0156] 5,5-dimethyl-3-phenylimidazolidine-2,4-dione (0.413 g, 2.022 mmol) prepared in step 2 was dissolved in N, N-dimethylformamide (15 mL) at 0 ° C, and sodium hydride (0.073 g, 3.033 mmol) was added to the resulting solution and stirred at the same temperature for 30 minutes. 4-(bromomethyl)-3-fluorobenzoic acid methyl ester (0.500 g, 2.022 mmol) was added to the reaction mixture and stirred for another 12 hours at room temperature. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with saturated sodium chloride aqueous solution, dehydrated with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane=0 to 30%), and concentrated to obtain the desired title compound (0.265 g, 35.4%) in the form of a colorless oil.
[0157] [Step 4] Synthesis of 4-((5,5-dimethyl-2,4-dioxo-3-phenylimidazolidin-1-yl)methyl)-3-fluorobenzohydrazide
[0158]
[0159] The methyl 4-((5,5-dimethyl-2,4-dioxo-3-phenylimidazolidin-1-yl)methyl)-3-fluorobenzoate (0.265 g, 0.715 mmol) prepared in step 3 and hydrazine monohydrate (0.676 mL, 14.310 mmol) were mixed in ethanol (10 mL) and then heated at 120° C. for one hour by microwave irradiation and then completed by lowering the temperature to room temperature. The solvent was removed from the reaction mixture under reduced pressure, and water was poured into the resulting concentrate, which was then extracted with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dehydrated with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting product was used without additional purification (0.220 g, 83.0%, white foamy solid).
[0160] [Step 5] Synthesis of 4-((5,5-dimethyl-2,4-dioxo-3-phenylimidazolidin-1-yl)methyl)-3-fluoro-N′-(2,2,2-trifluoroacetyl)benzohydrazide
[0161]
[0162] 4-((5,5-dimethyl-2,4-dioxo-3-phenylimidazolidin-1-yl)methyl)-3-fluorobenzohydrazide (0.108 g, 0.292 mmol), trifluoroacetic anhydride (0.037 mL, 0.262 mmol) and triethylamine (0.061 mL, 0.437 mmol) prepared in step 4 were dissolved in dichloromethane (10 mL) at room temperature, and the resulting solution was stirred at the same temperature for one hour. Water was poured into the reaction mixture and extracted with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dehydrated with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; dichloromethane / dichloromethane=0 to 10%) and concentrated to obtain the desired title compound (0.084 g, 61.8%) as a colorless oil.
[0163] [Step 6] Synthesis of Compound 2
[0164]
[0165] 4-((5,5-dimethyl-2,4-dioxo-3-phenylimidazolidin-1-yl)methyl)-3-fluoro-N′-(2,2,2-trifluoroacetyl)benzohydrazide (0.084 g, 0.180 mmol) prepared in step 5 and 1-methoxy-N-triethylaminosulfonyl-carboximidate (Burgess reagent, 0.064 g, 0.270 mmol) were mixed in tetrahydrofuran (10 mL), and the resulting mixture was irradiated with microwaves, and then heated at 150° C. for 30 minutes, and then the reaction was completed by lowering the temperature to room temperature. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated sodium chloride aqueous solution, dehydrated with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane = 0 to 50%) and concentrated to afford the desired compound (0.040 g, 49.5%) as a colorless oil.
[0166] 1 H NMR (400MHz, CDCl3) δ7.95~7.92 (m, 1H), 7.88 (dd, J=9.9, 1.5Hz, 1H), 7.78 (t, J=7.7Hz, 1H), 7.54~7.38 (m, 5H), 4.77 (s, 2H), 1.48 (s, 9H).
[0167] Synthesis of Compound 3,3-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-1-phenylimidazolidine-2,4-dione
[0168] [Step 1] Synthesis of 4-((2,5-dioxo-3-phenylimidazolidin-1-yl)methyl)-3-fluorobenzohydrazide
[0169]
[0170] Methyl 4-((4,4-dimethyl-2,5-dioxo-3-phenylimidazolidin-1-yl)methyl)-3-fluorobenzoate (0.175 g, 0.511 mmol) and hydrazine monohydrate (0.497 mL, 10.224 mmol) were dissolved in ethanol (3 mL) at room temperature, and the resulting solution was stirred at 120° C. for one hour, and then the reaction was completed by lowering the temperature to room temperature. The precipitated solid was filtered, washed with ethanol, and dried to obtain the title compound (0.100 g, 57.1%) as a white solid.
[0171] [Step 2] Synthesis of N′-(2,2-difluoroacetyl)-4-((2,5-dioxo-3-phenylimidazolidin-1-yl)methyl)-3-fluorobenzohydrazide
[0172]
[0173] 4-((2,5-dioxo-3-phenylimidazolidin-1-yl)methyl)-3-fluorobenzohydrazide (0.100 g, 0.292 mmol) prepared in step 1 and triethylamine (0.061 mL, 0.438 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and then 2,2-difluoroacetic anhydride (0.029 mL, 0.263 mmol) was added to the resulting solution and stirred at the same temperature for 17 hours. The precipitated solid was filtered, washed with dichloromethane, and dried to obtain the title compound (0.100 g, 81.4%) as a white solid.
[0174] [Step 3] Synthesis of Compound 3
[0175]
[0176] N'-(2,2-difluoroacetyl)-4-((2,5-dioxo-3-phenylimidazolidin-1-yl)methyl)-3-fluorobenzohydrazide (0.100 g, 0.238 mmol) prepared in step 2 and 1-methoxy-N-triethylaminosulfonyl-carboximidate (Burgess reagent, 0.085 g, 0.357 mmol) were mixed in tetrahydrofuran (3 mL) at room temperature, and the resulting mixture was irradiated with microwaves, and then heated at 150°C for 30 minutes, and then the reaction was completed by lowering the temperature to room temperature. The solvent was removed from the reaction mixture under reduced pressure, and water was poured into the resulting concentrate, and extraction was performed with dichloromethane, filtered through a plastic filter to remove the solid residue and the aqueous solution layer therefrom, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 4 g cartridge; ethyl acetate / hexane = 5 to 70%) and concentrated to afford the title compound (0.019 g, 19.9%) as a white solid.
[0177] 1 H NMR (400MHz, CDCl3) 67.89 (dd, J=4.8, 1.3Hz, 1H), 7.87 (t, J=2.2Hz, 1H), 7.69~7.38 (m, 6H), 7.14 (t, J=7.4Hz, 1H), 4.79 (s, 2H), 4.61 (s, 2H).
[0178] Synthesis of Compound 4,3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-phenylimidazolidine-2,4-dione
[0179]
[0180] 1-phenylimidazolidine-2,4-dione (0.200 g, 1.135 mmol) was dissolved in N, N-dimethylformamide (10 mL) at 0 ° C, and sodium hydride (60.00%, 0.068 g, 1.703 mmol) was added to the resulting solution and stirred at the same temperature for 30 minutes. 2-(6-(bromomethyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.329 g, 1.135 mmol) was added to the reaction mixture and stirred for another three hours at room temperature. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with saturated sodium chloride aqueous solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified and concentrated by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane=0 to 30%) to obtain the title compound (0.100 g, 22.9%) in the form of a white solid.
[0181] 1H NMR (400MHz, CDCl3) δ9.27~9.26 (m, 1H), 8.39 (dd, J=8.2, 2.2Hz, 1H), 7.61 (dd, J=7.8, 1.1Hz, 2H), 7.54 (dd, J=8.2, 0.7Hz, 1H), 7.44~7.40(m, 2H), 7.20~7.18(m, 1H), 7.08(s, 0.25H), 6.95(s, 0.5H), 6.82(s, 0.25H), 5.03(s, 2H), 4.47(s, 2H).; LRMS(ES) m / z 386.4(M + +1).
[0182] Synthesis of Compound 5, 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(3-fluorophenyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylic acid tert-butyl ester
[0183] [Step 1] Synthesis of tert-butyl 4-((3-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-3-phenylureido)methyl)piperidine-1-carboxylate
[0184]
[0185] 3-Fluoroaniline (1.000 g, 8.999 mmol), tert-butyl 4-oxopiperidine-1-carboxylate (1.793 g, 8.999 mmol) and trimethylsilylcarbonitrile (0.893 g, 8.999 mmol) were dissolved in acetic acid (30 mL), and the resulting solution was stirred at 0 ° C for 30 minutes and at room temperature for another 18 hours. Saturated aqueous ammonium chloride solution was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane=0 to 30%) and concentrated to obtain the title compound (1.850 g, 64.4%) as a white solid.
[0186] [Step 2] Synthesis of tert-butyl 1-(3-fluorophenyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate
[0187]
[0188] 4-cyano-4-((3-fluorophenyl)amino)piperidine-1-carboxylic acid tert-butyl ester (1.850g, 5.792mmol) prepared in step 1 is dissolved in dichloromethane (5mL), then chlorosulfonyl isocyanate (1.230g, 8.689mmol) is added to the resulting solution at 0°C and stirred for 30 minutes. 1N-aqueous hydrochloric acid solution (10mL) is poured into the reaction mixture, then the solvent is concentrated under reduced pressure, and then ethanol (15mL) is added. The resulting mixture is stirred again for 30 minutes at 80°C, and then the solvent is concentrated under reduced pressure. Thereafter, the resulting mixture is dissolved in THF (20mL) and adjusted to pH 8 with 10% potassium carbonate solution, then di-tert-butyl dicarbonate (1.896g, 8.689mmol) dissolved in THF (20mL) is added and stirred for 18 hours. Thereafter, the precipitated solid is filtered to obtain the desired title compound (1.23g, 59.9%) in the form of a white solid.
[0189] [Step 3] Synthesis of Compound 5
[0190]
[0191] 1-(3-Fluorophenyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylic acid tert-butyl ester (0.600 g, 1.651 mmol) prepared in step 2 was dissolved in N,N-dimethylformamide (10 mL) at 0°C, and sodium hydride (60.00%, 0.099 g, 2.477 mmol) was added to the resulting solution and stirred at the same temperature for 30 minutes. 2-(6-(bromomethyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.718 g, 2.477 mmol) was added to the reaction mixture and stirred at room temperature for another three hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with saturated sodium chloride aqueous solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane = 0 to 50%) and concentrated to afford the title compound (0.257 g, 27.2%) as a colorless oil.
[0192] 1H NMR (400MHz, CDCl3) δ9.22 (t, J=1.1Hz, 1H), 8.34 (dd, J=8.2, 2.2Hz, 1H), 7.48~ 7.39(m, 2H), 7.20~7.15(m, 1H), 7.06(s, 0.25H), 7.01~7.00(m, 1H), 6.98(s, 0. 5H), 6.99~6.94(m, 1H), 6.92(s, 0.25H), 4.95(s, 2H), 4.10~3.95(m, 2H), 3.50~ 3.40(m, 2H), 1.99~1.95(m, 2H), 1.80~1.75(m, 2H), 1.36(s, 9H).; LRMS(ES)m / z 573.4(M + +1).
[0193] Synthesis of Compound 6, 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(3-fluorophenyl)-8-methyl-1,3,8-triazaspiro[4.5]decane-2,4-dione
[0194] [Step 1] Synthesis of 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(3-fluorophenyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione 2,2,2-trifluoroacetate
[0195]
[0196] Tert-butyl 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(3-fluorophenyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carboxylate (0.257 g, 0.449 mmol) and trifluoroacetic acid (0.344 mL, 4.489 mmol) were dissolved in dichloromethane (30 mL) at room temperature, and the resulting solution was stirred at the same temperature for 12 hours. The solvent was removed from the reaction mixture under reduced pressure, and the resulting product was used without further purification (0.250 g, 95.0%, yellow oil).
[0197] [Step 2] Synthesis of Compound 6
[0198]
[0199] 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(3-fluorophenyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione 2,2,2-trifluoroacetate (0.200 g, 0.341 mmol) prepared in step 1, formaldehyde (0.020 g, 0.682 mmol), N,N-diisopropylethylamine (0.059 mL, 0.341 mmol) and sodium triacetoxyborohydride (0.145 g, 0.682 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and the resulting solution was stirred at the same temperature for two hours. Water was poured into the reaction mixture and extracted with dichloromethane. The organic layer was washed with a saturated sodium chloride aqueous solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; methanol / dichloromethane = 0 to 10%) and concentrated to afford the title compound (0.100 g, 60.3%) as a colorless oil.
[0200] 1 H NMR (400MHz, CDCl3) δ9.28 (d, J=1.4Hz, 1H), 8.41 (dd, J=8.2, 2.2Hz, 1H), 7.51 ( d, J=8.2Hz, 1H), 7.47~7.41(m, 1H), 7.18~7.14(m, 1H), 7.08(s, 0.25H), 7.05~7. 03(m, 1H), 7.00~6.97(m, 1H), 6.95(s, 0.5H), 6.82(s, 0.25H), 5.00(s, 2H), 3.20 ~2.90(m, 4H), 2.48(s, 3H), 2.23~2.20(m, 2H), 2.08~2.05(m, 2H).; LRMS(ES)m / z 487.5(M + +1).
[0201] Synthesis of Compound 7, 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(3-fluorophenyl)-8-(oxetane-3-yl)-1,3,8-triazaspiro[4.5]decane-2,4-dione
[0202]
[0203] N′-(2,2-difluoroacetyl)-6-((1-(3-fluorophenyl)-8-(oxetane-3-yl)-2,4-dioxo-1,3,8-triazaspiro[4.5]dec-3-yl)methyl)nicotinic acid hydrazide (0.060 g, 0.110 mmol) and 1-methoxy-N-triethylaminosulfonyl-carboximidate (Burgess reagent, 0.052 g, 0.220 mmol) were dissolved in tetrahydrofuran (5 mL) at 80° C., and the resulting solution was stirred at the same temperature for 13 hours, and then the reaction was completed by lowering the temperature to room temperature. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated sodium chloride aqueous solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane = 0 to 100%) and concentrated to afford the title compound (0.020 g, 34.5%) as a colorless oil.
[0204] 1 H NMR (400MHz, CDCl3) δ9.28 (dd, J=2.2, 0.8Hz, 1H), 8.39 (dd, J=8.2, 2.2Hz, 1H), 7.51~ 7.49(m, 1H), 7.47~7.43(m, 1H), 7.21~7.16(m, 1H), 7.08~7.05(m, 1H), 7.08(s, 0.25H ), 7.01~6.98(m, 1H), 6.95(s, 0.5H), 6.82(s, 0.25H), 4.99(s, 2H), 4.66(t, J=6.6Hz, 2H), 4.55 (t, J=5.0Hz, 2H), 3.61~3.58(m, 1H), 2.74~2.66(m, 4H), 2.11~2.04(m, 4H).
[0205] Synthesis of Compound 8, 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(3-fluorophenyl)-8-isopropyl-1,3,8-triazaspiro[4.5]decane-2,4-dione
[0206]
[0207] 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(3-fluorophenyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione 2,2,2-trifluoroacetate (0.200 g, 0.341 mmol), acetone (0.051 mL, 0.682 mmol), N,N-diisopropylethylamine (0.059 mL, 0.341 mmol) and sodium triacetoxyborohydride (0.145 g, 0.682 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and the resulting solution was stirred at the same temperature for 18 hours. Water was poured into the reaction mixture and extracted with dichloromethane. The organic layer was washed with a saturated sodium chloride aqueous solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; methanol / dichloromethane = 0 to 10%) and concentrated to afford the title compound (0.110 g, 62.8%) as a white foamy solid.
[0208] 1 H NMR (400MHz, CDCl3) δ9.29 (dd, J=2.1, 0.7Hz, 1H), 8.41 (dd, J=8.2, 2.2Hz, 1H), 7.53~7 .50(m, lH), 7.47~7.43(m, 1H), 7.19~7.16(m, lH), 7.08(s, 0.25H), 7.01~7.00(m, lH), 6 .99~6.98 (m, 1H), 6.96 (s, 0.5H), 6.83 (s, 0.25H), 5.00 (s, 2H), 3.28~3.25 (m, 1H), 3.1 0~3.08(m, 4H), 2.33~2.30(m, 2H), 2.09~2.06(m, 2H), 1.18~1.13(m, 6H).; LRMS(ES)m / z 515.5(M + +1).
[0209] Synthesis of Compound 9, 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-yl)methyl)-1-phenylimidazolidine-2,4-dione
[0210]
[0211] 1-Phenylimidazolidine-2,4-dione (0.300 g, 1.703 mmol), 2-(2-(bromomethyl)pyrimidin-5-yl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.496 g, 1.703 mmol) and potassium carbonate (0.353 g, 2.554 mmol) were dissolved in N,N-dimethylformamide (5 mL) at 80°C, and the resulting solution was stirred at the same temperature for 12 hours, and then the reaction was completed by lowering the temperature to room temperature. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane=0 to 50%) and concentrated to obtain the title compound (0.110 g, 16.7%) as a yellow solid.
[0212] 1 H NMR (400MHz, CDCl3) δ9.37 (s, 2H), 7.65~7.62 (m, 2H), 7.46~7.42 (m, 2H), 7.23~7.19 (m, 1H) , 7.10 (s, 0.25H), 6.97 (s, 0.5H), 6.84 (s, 0.25H), 5.18 (s, 2H), 4.52 (s, 2H).; LRMS (ES) m / z 387.3(M + +1).
[0213] Compound 10, Synthesis of 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(3-fluorophenyl)-5,5-dimethylimidazolidine-2,4-dione
[0214] [Step 1] Synthesis of 2-((3-fluorophenyl)amino)-2-methylpropionitrile
[0215]
[0216] 3-Fluoroaniline (1.000 g, 8.999 mmol), trimethylsilylcarbonitrile (0.893 g, 8.999 mmol) and propan-2-one (0.523 g, 8.999 mmol) were dissolved in acetone (20 mL) at room temperature, and the resulting solution was stirred at the same temperature for 12 hours. Saturated aqueous ammonium chloride solution was poured into the reaction mixture, and extracted with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 40 g cartridge; ethyl acetate / hexane=0 to 20%) and concentrated to obtain the title compound (1.240 g, 77.3%) as a white solid.
[0217] [Step 2] Synthesis of 1-(3-fluorophenyl)-5,5-dimethylimidazolidine-2,4-dione
[0218]
[0219] 2-(3-Fluorophenyl)-2-methylpropionitrile (1.240 g, 7.598 mmol) and chlorosulfonyl isocyanate (1.613 g, 11.397 mmol) prepared in step 1 were dissolved in dichloromethane (10 mL) at room temperature, and the resulting solution was stirred for one hour at the same temperature. 1N-hydrochloric acid aqueous solution (10 mL) was poured into the reaction mixture, and the solvent was concentrated under reduced pressure, and then ethanol (15 mL) was added. The resulting mixture was stirred again at 80° C. for 30 minutes, and the solvent was concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane=0 to 30%) and concentrated to obtain the title compound (0.880 g, 52.1%) as a white solid.
[0220] [Step 3] Synthesis of compound 10
[0221]
[0222] 1-(3-Fluorophenyl)-5,5-dimethylimidazolidine-2,4-dione (0.100 g, 0.450 mmol), 2-(6-(bromomethyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.144 g, 0.495 mmol) and potassium carbonate (0.124 g, 0.900 mmol) prepared in step 2 were dissolved in N,N-dimethylformamide (10 mL), and the resulting solution was stirred at 50° C. for 18 hours and then at room temperature for another 18 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane=0 to 80%) and concentrated to obtain the title compound (0.130 g, 67.0%) as a white solid.
[0223] 1H NMR (400MHz, CDCl3) δ9.26 (t, J=1.1Hz, 1H), 8.37 (dd, J=8.2, 2.2Hz, 1H), 7.49 (d, J=8.2Hz, 1H), 7.43~7.40 (m, 1 H), 7.14~7.06 (m, 3H), 7.08 (s, 0.25H), 6.95 (s, 0.5H), 6.82 (s, 0.25H), 5.00 (s, 2H), 1.55 (s, 6H).; LRMS (ES) m / z 432.3(M + +1).
[0224] Synthesis of Compound 11, 1-(3-bromophenyl)-3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethylimidazolidine-2,4-dione
[0225] [Step 1] Synthesis of 2-((3-bromophenyl)amino)-2-methylpropionitrile
[0226]
[0227] 3-Bromoaniline (2.000 g, 11.626 mmol), trimethylsilylcarbonitrile (1.153 g, 11.626 mmol) and propan-2-one (0.675 g, 11.626 mmol) were dissolved in acetone (20 mL) at room temperature, and the resulting solution was stirred at the same temperature for 12 hours. Saturated aqueous ammonium chloride solution was poured into the reaction mixture, and extracted with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 40 g cartridge; ethyl acetate / hexane=0 to 20%) and concentrated to obtain the title compound (2.200 g, 79.1%) as a brown oil.
[0228] [Step 2] Synthesis of 1-(3-bromophenyl)-5,5-dimethylimidazolidine-2,4-dione
[0229]
[0230] 2-(3-Bromophenyl)-2-methylpropionitrile (2.200 g, 9.817 mmol) and chlorosulfonyl isocyanate (2.084 g, 14.726 mmol) prepared in step 1 were dissolved in dichloromethane (10 mL) at room temperature, and the resulting solution was stirred for one hour at the same temperature. 1N-hydrochloric acid aqueous solution (10 mL) was poured into the reaction mixture, and the solvent was concentrated under reduced pressure, and then ethanol (15 mL) was added. The resulting mixture was stirred again at 80° C. for 30 minutes, and the solvent was concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane=0 to 30%) and concentrated to obtain the title compound (1.500 g, 54.0%) in the form of a white solid.
[0231] [Step 3] Synthesis of compound 11
[0232]
[0233] 1-(3-Bromophenyl)-5,5-dimethylimidazolidine-2,4-dione (0.892 g, 3.150 mmol), 2-(6-(bromomethyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole (1.005 g, 3.466 mmol) and potassium carbonate (0.871 g, 6.301 mmol) prepared in step 2 were dissolved in N,N-dimethylformamide (10 mL), and the resulting solution was stirred at 50° C. for 18 hours and then at room temperature for another 18 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane=0 to 80%) and concentrated to obtain the title compound (1.100 g, 70.9%) as a yellow oil.
[0234] 1 H NMR (400MHz, CDCl3) δ9.30 (t, J=1.1Hz, 1H), 8.41 (dd, J=8.2, 2.2Hz, 1H), 7.57~7.55 (m, 1H), 7.51~7.49 (m, 1H), 7.36 (t, J =8.0Hz, 1H), 7.30~7.27(m, 2H), 7.09(s, 0.25H), 6.95(s, 0.5H), 6.83(s, 0.25H), 5.03(s, 2H), 1.59(s, 6H).; LRMS(ES) m / z 494.2(M + +1).
[0235] Synthesis of Compound 12, 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(4-fluorophenyl)-5,5-dimethylimidazolidine-2,4-dione
[0236] [Step 1] Synthesis of 2-((4-fluorophenyl)amino)-2-methylpropionitrile
[0237]
[0238] 4-Fluoroaniline (1.000 g, 8.999 mmol), trimethylsilylcarbonitrile (0.893 g, 8.999 mmol) and propan-2-one (0.523 g, 8.999 mmol) were dissolved in acetone (20 mL) at room temperature, and the resulting solution was stirred at the same temperature for 12 hours. Saturated aqueous ammonium chloride solution was poured into the reaction mixture and extracted with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 40 g cartridge; ethyl acetate / hexane=0 to 20%) and concentrated to obtain the title compound (0.535 g, 33.4%) as a white solid.
[0239] [Step 2] Synthesis of 1-(4-fluorophenyl)-5,5-dimethylimidazolidine-2,4-dione
[0240]
[0241] 2-(4-Fluorophenyl)-2-methylpropionitrile (0.530 g, 3.248 mmol) and chlorosulfonyl isocyanate (0.689 g, 4.871 mmol) prepared in step 1 were dissolved in dichloromethane (10 mL) at room temperature, and the resulting solution was stirred for one hour at the same temperature. 1N-hydrochloric acid aqueous solution (10 mL) was poured into the reaction mixture, and the solvent was concentrated under reduced pressure, and then ethanol (15 mL) was added. The resulting mixture was stirred again at 80° C. for 30 minutes, and the solvent was concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane=0 to 30%) and concentrated to obtain the title compound (0.330 g, 45.7%) in the form of a white solid.
[0242] [Step 3] Synthesis of compound 12
[0243]
[0244] 1-(4-Fluorophenyl)-5,5-dimethylimidazolidine-2,4-dione (0.100 g, 0.450 mmol), 2-(6-(bromomethyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.144 g, 0.495 mmol) and potassium carbonate (0.124 g, 0.900 mmol) prepared in step 2 were dissolved in N,N-dimethylformamide (10 mL), and the resulting solution was stirred at 50° C. for 18 hours and then at room temperature for another 18 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane=0 to 80%) and concentrated to obtain the title compound (0.110 g, 56.7%) as a white solid.
[0245] 1 H NMR (400MHz, CDCl3) δ9.27 (t, J=1.1Hz, 1H), 8.38 (dd, J=8.2, 2.2Hz, 1H), 7.49 (d, J=8.2Hz, 1H), 7.30~7.26 (m, 2 H), 7.17~7.13 (m, 2H), 7.08 (s, 0.25H), 6.95 (s, 0.5H), 6.82 (s, 0.25H), 5.01 (s, 2H), 1.52 (s, 6H).; LRMS (ES) m / z 432.3(M + +1).
[0246] Synthesis of Compound 13, 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(2,6-difluorophenyl)-5,5-dimethylimidazolidine-2,4-dione
[0247] [Step 1] Synthesis of 2-((2,6-difluorophenyl)amino)-2-methylpropionitrile
[0248]
[0249] 2,6-Difluoroaniline (0.781 mL, 7.745 mmol), trimethylsilylcarbonitrile (0.973 mL, 7.745 mmol) and propan-2-one (0.569 mL, 7.745 mmol) were dissolved in acetic acid (10 mL) at room temperature, and the resulting solution was stirred at the same temperature for 18 hours. The solvent was removed from the reaction mixture under reduced pressure, and hexane (20 mL) and ethyl acetate (10 mL) were added to the resulting concentrate and stirred to filter out the precipitated solid, wash with hexane, and dry to obtain the title compound (0.330 g, 21.7%) as a white solid.
[0250] [Step 2] Synthesis of 1-(2,6-difluorophenyl)-5,5-dimethylimidazolidine-2,4-dione
[0251]
[0252] 2-((2,6-difluorophenyl)amino)-2-methylpropionitrile (0.330 g, 1.682 mmol) prepared in step 1 and chlorosulfonyl isocyanate (0.357 g, 2.523 mmol) were dissolved in dichloromethane (50 mL), and the resulting solution was stirred at 0°C for 30 minutes and at room temperature for another 18 hours. 1N-hydrochloric acid aqueous solution (10 mL) was poured into the reaction mixture, and the solvent was concentrated under reduced pressure, and then ethanol (30 mL) was added. The resulting mixture was stirred again at 80°C for 30 minutes, and the solvent was concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO:, 12 g cartridge; ethyl acetate / hexane=0 to 50%) and concentrated to obtain the title compound (0.100 g, 24.8%) as a white solid.
[0253] [Step 3] Synthesis of compound 13
[0254]
[0255] 1-(2,6-difluorophenyl)-5,5-dimethylimidazolidine-2,4-dione (0.100 g, 0.416 mmol) prepared in step 2, 2-(6-(bromomethyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.121 g, 0.416 mmol) and potassium carbonate (0.115 g, 0.833 mmol) were dissolved in N,N-dimethylformamide (5 mL) at 80°C, and the resulting solution was stirred at the same temperature for 18 hours, and then the reaction was completed by lowering the temperature to room temperature. The solvent was removed from the reaction mixture under reduced pressure, and water was poured into the resulting concentrate, followed by extraction with dichloromethane. The organic layer was washed with a saturated sodium chloride aqueous solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO 2 , 12 g cartridge; ethyl acetate / hexane=0 to 50%) and concentrated to afford the title compound (0.150 g, 80.2%) as a white solid.
[0256] 1 H NMR (400MHz, CDCl3) δ9.30 (dd, J=2.2, 0.8Hz, 1H), 8.40 (dd, J=8.2, 2.2Hz, 1H), 7.48~7.39 (m, 2H), 7.09 ~7.05(m, 2H), 7.08(s, 0.25H), 6.95(s, 0.5H), 6.82(s, 0.25H), 5.04(s, 2H), 1.54(s, 6H).; LRMS(ES)m / z 450.2(M + +1).
[0257] Compound 14, Synthesis of 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(2,4-difluorophenyl)-5,5-dimethylimidazolidine-2,4-dione
[0258] [Step 1] Synthesis of 2-((2,4-difluorophenyl)amino)-2-methylpropionitrile
[0259]
[0260] 2,4-Difluoroaniline (1.000 g, 7.745 mmol), trimethylsilylcarbonitrile (0.768 g, 7.745 mmol) and propan-2-one (0.450 g, 7.745 mmol) were dissolved in acetic acid (10 mL) at room temperature, and the resulting solution was stirred at the same temperature for 18 hours. The solvent was removed from the reaction mixture under reduced pressure, and hexane (20 mL) and ethyl acetate (10 mL) were added to the resulting concentrate and stirred to filter out the precipitated solid, wash with hexane, and dry to obtain the title compound (1.000 g, 65.8%) as a white solid.
[0261] [Step 2] Synthesis of 1-(2,4-difluorophenyl)-5,5-dimethylimidazolidine-2,4-dione
[0262]
[0263] 2-((2,4-difluorophenyl)amino)-2-methylpropionitrile (1.000 g, 5.097 mmol) prepared in step 1 and chlorosulfonyl isocyanate (1.082 g, 7.645 mmol) were dissolved in dichloromethane (50 mL), and the resulting solution was stirred at 0° C. for 30 minutes and at room temperature for another 18 hours. 1N-hydrochloric acid aqueous solution (10 mL) was poured into the reaction mixture, and the solvent was concentrated under reduced pressure, and then ethanol (30 mL) was added. The resulting mixture was stirred again at 80° C. for 30 minutes, and the solvent was concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane=0 to 50%) and concentrated to obtain the title compound (0.700 g, 57.2%) as a white solid.
[0264] [Step 3] Synthesis of compound 14
[0265]
[0266] 1-(2,4-difluorophenyl)-5,5-dimethylimidazolidine-2,4-dione (0.100 g, 0.416 mmol) prepared in step 2, 2-(6-(bromomethyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.121 g, 0.416 mmol) and potassium carbonate (0.115 g, 0.833 mmol) were dissolved in N,N-dimethylformamide (5 mL) at 80°C, and the resulting solution was stirred at the same temperature for 18 hours, and then the reaction was completed by lowering the temperature to room temperature. The solvent was removed from the reaction mixture under reduced pressure, and water was poured into the resulting concentrate, followed by extraction with dichloromethane. The organic layer was washed with a saturated sodium chloride aqueous solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO 2 , 12 g cartridge; ethyl acetate / hexane=0 to 50%) and concentrated to afford the title compound (0.130 g, 69.5%) as a white solid.
[0267] 1 H NMR (400MHz, CDCl3) δ9.30 (d, J=2.2Hz, 1H), 8.40 (dd, J=8.2, 2.2Hz, 1H), 7.49 (d, J=8.2Hz, 1H), 7.31~7.28 (m, 1 H), 7.08 (s, 0.25H), 7.04~6.99 (m, 2H), 6.95 (s, 0.5H), 6.82 (s, 0.25H), 5.03 (s, 2H), 1.52 (s, 6H).; LRMS (ES) m / z 450.2(M + +1).
[0268] Synthesis of Compound 15, 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(2,3-difluorophenyl)-5,5-dimethylimidazolidine-2,4-dione
[0269] [Step 1] Synthesis of 2-((2,3-difluorophenyl)amino)-2-methylpropionitrile
[0270]
[0271] 2,3-Difluoroaniline (1.000 g, 7.745 mmol), trimethylsilylcarbonitrile (0.768 g, 7.745 mmol) and propan-2-one (0.450 g, 7.745 mmol) were dissolved in acetic acid (10 mL) at room temperature, and the resulting solution was stirred at the same temperature for 18 hours. The solvent was removed from the reaction mixture under reduced pressure, and hexane (20 mL) and ethyl acetate (10 mL) were added to the resulting concentrate and stirred to filter out the precipitated solid, wash with hexane, and dry to obtain the title compound (1.100 g, 72.4%) as a white solid.
[0272] [Step 2] Synthesis of 1-(2,3-difluorophenyl)-5,5-dimethylimidazolidine-2,4-dione
[0273]
[0274] 2-((2,3-difluorophenyl)amino)-2-methylpropionitrile (1.100 g, 5.607 mmol) prepared in step 1 and chlorosulfonyl isocyanate (1.190 g, 8.410 mmol) were dissolved in dichloromethane (50 mL), and the resulting solution was stirred at 0° C. for 30 minutes and at room temperature for another 18 hours. 1N-hydrochloric acid aqueous solution (10 mL) was poured into the reaction mixture, and the solvent was concentrated under reduced pressure, and then ethanol (30 mL) was added. The resulting mixture was stirred again at 80° C. for 30 minutes, and the solvent was concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO:, 12 g cartridge; ethyl acetate / hexane=0 to 50%) and concentrated to obtain the title compound (0.800 g, 59.4%) as a white solid.
[0275] [Step 3] Synthesis of compound 15
[0276]
[0277] 1-(2,3-difluorophenyl)-5,5-dimethylimidazolidine-2,4-dione (0.100 g, 0.416 mmol) prepared in step 2, 2-(6-(bromomethyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.121 g, 0.416 mmol) and potassium carbonate (0.115 g, 0.833 mmol) were dissolved in N,N-dimethylformamide (5 mL) at 80°C, and the resulting solution was stirred at the same temperature for 18 hours, and then the reaction was completed by lowering the temperature to room temperature. The solvent was removed from the reaction mixture under reduced pressure, and water was poured into the resulting concentrate, followed by extraction with dichloromethane. The organic layer was washed with a saturated sodium chloride aqueous solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO 2 , 12 g cartridge; ethyl acetate / hexane=0 to 50%) and concentrated to afford the title compound (0.150 g, 80.2%) as a white solid.
[0278] 1 H NMR (400MHz, CDCl3) δ9.30 (dd, J=3.0, 1.7Hz, 1H), 8.41 (dd, J=8.2, 2.2Hz, 1H), 7.50 (dd, J=8.2, 0.7Hz, 1H), 7.31~7.28 (m, 1H), 7.21~7.19 (m, 1H), 7.12~7.08 (m, 1H), 7.08 (s, 0.25H), 6.95 (s, 0.5H), 6.82 (s, 0.25H), 5.04 (s, 2H), 1.54 (s, 6H).; LRMS (ES) m / z 450.2(M + +1).
[0279] Synthesis of Compound 16, 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(3,4-difluorophenyl)-5,5-dimethylimidazolidine-2,4-dione
[0280] [Step 1] Synthesis of 2-((3,4-difluorophenyl)amino)-2-methylpropionitrile
[0281]
[0282] 3,4-Difluoroaniline (1.000 g, 7.745 mmol), trimethylsilylcarbonitrile (0.768 g, 7.745 mmol) and propan-2-one (0.450 g, 7.745 mmol) were dissolved in acetic acid (10 mL) at room temperature, and the resulting solution was stirred at the same temperature for 18 hours. The solvent was removed from the reaction mixture under reduced pressure, and hexane (20 mL) and ethyl acetate (10 mL) were added to the resulting concentrate and stirred to filter out the precipitated solid, wash with hexane, and dry to obtain the title compound (0.700 g, 46.1%) as a white solid.
[0283] [Step 2] Synthesis of 1-(3,4-difluorophenyl)-5,5-dimethylimidazolidine-2,4-dione
[0284]
[0285] 2-((3,4-difluorophenyl)amino)-2-methylpropionitrile (0.700 g, 3.568 mmol) prepared in step 1 and chlorosulfonyl isocyanate (0.757 g, 5.352 mmol) were dissolved in dichloromethane (50 mL), and the resulting solution was stirred at 0° C. for 30 minutes and at room temperature for another 18 hours. 1N-hydrochloric acid aqueous solution (10 mL) was poured into the reaction mixture, and the solvent was concentrated under reduced pressure, and then ethanol (30 mL) was added. The resulting mixture was stirred again at 80° C. for 30 minutes, and the solvent was concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane=0 to 50%) and concentrated to obtain the title compound (0.450 g, 52.5%) as a white solid.
[0286] [Step 3] Synthesis of compound 16
[0287]
[0288] 1-(3,4-difluorophenyl)-5,5-dimethylimidazolidine-2,4-dione (0.100 g, 0.416 mmol) prepared in step 2, 2-(6-(bromomethyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.121 g, 0.416 mmol) and potassium carbonate (0.115 g, 0.833 mmol) were dissolved in N,N-dimethylformamide (5 mL) at 80°C, and the resulting solution was stirred at the same temperature for 18 hours, and then the reaction was completed by lowering the temperature to room temperature. The solvent was removed from the reaction mixture under reduced pressure, and water was poured into the resulting concentrate, followed by extraction with dichloromethane. The organic layer was washed with a saturated sodium chloride aqueous solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO 2 , 12 g cartridge; ethyl acetate / hexane=0 to 50%) and concentrated to afford the title compound (0.130 g, 69.5%) as a white solid.
[0289] 1 H NMR (400MHz, CDCl3) δ9.28 (t, J=1.1Hz, 1H), 8.40 (dd, J=8.2, 2.2Hz, 1H), 7.51~7.49 (m, 1H), 7.28~7.19 (m, 2H) , 7.09~7.08 (m, 1H), 7.08 (s, 0.25H), 6.95 (s, 0.5H), 6.82 (s, 0.25H), 5.01 (s, 2H), 1.55 (s, 6H).; LRMS (ES) m / z 450.4(M + +1).
[0290] Compound 17, Synthesis of 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(3,5-difluorophenyl)-5,5-dimethylimidazolidine-2,4-dione
[0291] [Step 1] Synthesis of 2-((3,5-difluorophenyl)amino)-2-methylpropionitrile
[0292]
[0293] 3,5-Difluoroaniline (1.000 g, 7.745 mmol), trimethylsilylcarbonitrile (0.768 g, 7.745 mmol) and propan-2-one (0.450 g, 7.745 mmol) were dissolved in acetic acid (10 mL) at room temperature, and the resulting solution was stirred at the same temperature for 18 hours. The solvent was removed from the reaction mixture under reduced pressure, and hexane (20 mL) and ethyl acetate (10 mL) were added to the resulting concentrate and stirred to filter out the precipitated solid, wash with hexane, and dry to obtain the title compound (1.100 g, 72.4%) as a white solid.
[0294] [Step 2] Synthesis of 1-(3,5-difluorophenyl)-5,5-dimethylimidazolidine-2,4-dione
[0295]
[0296] 2-((3,5-difluorophenyl)amino)-2-methylpropionitrile (1.100 g, 5.607 mmol) prepared in step 1 and chlorosulfonyl isocyanate (1.190 g, 8.410 mmol) were dissolved in dichloromethane (50 mL), and the resulting solution was stirred at 0° C. for 30 minutes and at room temperature for another 18 hours. 1N-hydrochloric acid aqueous solution (10 mL) was poured into the reaction mixture, and the solvent was concentrated under reduced pressure, and then ethanol (30 mL) was added. The resulting mixture was stirred again at 80° C. for 30 minutes, and the solvent was concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane=0 to 50%) and concentrated to obtain the title compound (0.800 g, 59.4%) as a white solid.
[0297] [Step 3] Synthesis of compound 17
[0298]
[0299] 1-(3,5-difluorophenyl)-5,5-dimethylimidazolidine-2,4-dione (0.100 g, 0.416 mmol) prepared in step 2, 2-(6-(bromomethyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.121 g, 0.416 mmol) and potassium carbonate (0.115 g, 0.833 mmol) were dissolved in N,N-dimethylformamide (5 mL) at 80°C, and the resulting solution was stirred at the same temperature for 18 hours, and then the reaction was completed by lowering the temperature to room temperature. The solvent was removed from the reaction mixture under reduced pressure, and water was poured into the resulting concentrate, followed by extraction with dichloromethane. The organic layer was washed with a saturated sodium chloride aqueous solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO 2 , 12 g cartridge; ethyl acetate / hexane=0 to 50%) and concentrated to afford the title compound (0.110 g, 58.8%) as a white solid.
[0300] 1 H NMR (400MHz, CDCl3) δ9.28 (t, J=1.1Hz, 1H), 8.41 (dd, J=8.2, 2.2Hz, 1H), 7.51 (d, J=8.2Hz, 1H), 7.09~7.08 (m, 1 H), 7.08 (s, 0.25H), 6.97~6.94 (m, 2H), 6.95 (s, 0.5H), 6.82 (s, 0.25H), 5.02 (s, 2H), 1.61 (s, 6H).; LRMS (ES) m / z 450.2(M + +1).
[0301] Synthesis of Compound 18, 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethyl-1-phenylimidazolidine-2,4-dione
[0302] [Step 1] Synthesis of 2-methyl-2-(phenylamino)propionitrile
[0303]
[0304] Aniline (0.980 mL, 10.738 mmol), trimethylsilylcarbonitrile (1.065 g, 10.738 mmol) and propan-2-one (0.624 g, 10.738 mmol) were dissolved in acetic acid (10 mL) at room temperature, and the resulting solution was stirred at the same temperature for 18 hours. The solvent was removed from the reaction mixture under reduced pressure, and hexane (20 mL) and ethyl acetate (10 mL) were added to the resulting concentrate and stirred to filter out the precipitated solid, wash with hexane, and dry to obtain the title compound (1.100 g, 63.9%) as a white solid.
[0305] [Step 2] Synthesis of 5,5-dimethyl-1-phenylimidazolidine-2,4-dione
[0306]
[0307] 2-Methyl-2-(phenylamino)propionitrile (1.100 g, 6.866 mmol) prepared in step 1 and chlorosulfonyl isocyanate (1.458 g, 10.298 mmol) were dissolved in dichloromethane (50 mL), and the resulting solution was stirred at 0° C. for 30 minutes and at room temperature for another 18 hours. 1N-hydrochloric acid aqueous solution (10 mL) was poured into the reaction mixture, and the solvent was concentrated under reduced pressure, and then ethanol (30 mL) was added. The resulting mixture was stirred again at 80° C. for 30 minutes, and the solvent was concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane=0 to 50%) and concentrated to obtain the title compound (0.600 g, 42.8%) as a white solid.
[0308] [Step 3] Synthesis of compound 18
[0309]
[0310] 5,5-dimethyl-1-phenylimidazolidine-2,4-dione (0.100 g, 0.490 mmol) prepared in step 2, 2-(6-(bromomethyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.142 g, 0.490 mmol) and potassium carbonate (0.135 g, 0.979 mmol) were dissolved in N,N-dimethylformamide (5 mL) at 80°C, and the resulting solution was stirred at the same temperature for 18 hours, and then the reaction was completed by lowering the temperature to room temperature. The solvent was removed from the reaction mixture under reduced pressure, and water was poured into the resulting concentrate, followed by extraction with dichloromethane. The organic layer was washed with a saturated sodium chloride aqueous solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane = 0 to 50%) and concentrated to afford the title compound (0.080 g, 39.5%) as a white solid.
[0311] 1 H NMR (400MHz, CDCl3) δ9.26~9.25(m, 1H), 8.37~8.34(m, 1H), 7.49~7.38(m, 4H), 7.31~7.23(m, 2H), 7.08(s, 0.25H), 6.95(s, 0.5H), 6.82(s, 0.25H), 5.02(s, 2H), 1.52(s, 6H).; LRMS(ES)m / z 414.2(M + +1).
[0312] Compound 19, Synthesis of 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethyl-1-(3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)imidazolidine-2,4-dione
[0313] [Step 1] Synthesis of tert-butyl 4-(3-(3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)phenyl)-3,6-dihydropyridine-1(2H)-carboxylate
[0314]
[0315] 1-(3-bromophenyl)-3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethylimidazolidine-2,4-dione (0.200 g, 0.406 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester (0.2 51g, 0.813mmol), [1,1'-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (0.026g, 0.041mmol) and cesium carbonate (0.199g, 0.609mmol) were mixed in 1,2-dichloroethane (6mL) / water (2mL), and the resulting mixture was irradiated with microwaves, heated at 100°C for 20 minutes, and the reaction was completed by lowering the temperature to room temperature. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified and concentrated by column chromatography (SiO2, 12g cartridge; ethyl acetate / hexane=0 to 70%) to obtain the title compound (0.140g, 58.0%) as a colorless oil.
[0316] [Step 2] Synthesis of 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethyl-1-(3-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)imidazolidine-2,4-dione 2,2,2-trifluoroacetate
[0317]
[0318] Tert-butyl 4-(3-(3-((5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)phenyl)-3,6-dihydropyridine-1(2H)-carboxylate (0.140 g, 0.235 mmol) prepared in step 1 and trifluoroacetic acid (0.180 mL, 2.354 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and the resulting solution was stirred at the same temperature for 18 hours. The solvent was removed from the reaction mixture under reduced pressure, and the resulting product was used without further purification (0.140 g, 97.7%, brown oil).
[0319] [Step 3] Synthesis of compound 19
[0320]
[0321] 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethyl-1-(3-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)imidazolidine-2,4-dione 2,2,2-trifluoroacetate (0.080 g, 0.131 mmol) prepared in step 2, formaldehyde (0.008 g, 0.263 mmol), N,N-diisopropylethylamine (0.023 mL, 0.131 mmol) and sodium triacetoxyborohydride (0.056 g, 0.263 mmol) were dissolved in dichloromethane (5 mL) at room temperature, and the resulting solution was stirred at the same temperature for 18 hours. Water was poured into the reaction mixture and extracted with dichloromethane. The organic layer was washed with a saturated sodium chloride aqueous solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; methanol / dichloromethane = 0 to 10%) and concentrated to afford the title compound (0.040 g, 59.8%) as a colorless oil.
[0322] 1 H NMR (400MHz, CDCl3) δ9.29 (t, J=1.1Hz, 1H), 8.39 (dd, J=8.2, 2.2Hz, 1H), 7.50 ~7.48 (m, 1H), 7.41 ~ 7.39 (m, 2H), 7.29 ~ 7.28 (m, 1H), 7.20 ~ 7.18 (m, 1H), 7.08 (s , 0.25H), 6.95 (s, 0.5H), 6.82 (s, 0.25H), 6.10~6.08 (m, 1H), 5.02 (s, 2H), 3.16 ~3.15 (m, 2H), 2.70 ~ 2.69 (m, 2H), 2.61 ~ 2.60 (m, 2H), 2.43 (s, 3H), 1.53 (s, 6H).
[0323] Compound 20, Synthesis of 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethyl-1-(3-(1-methylpiperidin-4-yl)phenyl)imidazolidine-2,4-dione
[0324]
[0325] 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethyl-1-(3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)imidazolidine-2,4-dione (0.034 g, 0.067 mmol) was dissolved in methanol (10 mL) at room temperature, and then 10%-Pd / C (60 mg) was slowly added and stirred at the same temperature for 18 hours in the presence of a hydrogen balloon attached thereto. The reaction mixture was filtered through a celite pad to remove solids therefrom, and then the solvent was removed from the obtained filtrate under reduced pressure, and then the obtained product was used without additional purification treatment (0.028 g, 82.0%, colorless oil).
[0326] 1 H NMR(400MHz, CDCl3)δd 9.30~9.29 (m, 1H), 8.40 (dd, J=8.2, 2.2Hz, 1H), 7.50 (d, J=8.2Hz, 1H), 7.41~7. 37(m, 1H), 7.29~7.27(m, 1H), 7.16~7.14(m, 2H), 7.08(s, 0.25H), 6.95(s, 0.5H) ), 6.82(s, 0.25H), 5.02(s, 2H), 3.20~3.18(m, 2H), 2.62~2.55(m, 1H), 2.45(s, 3H), 2.29~2.25(m, 2H), 2.02~1.90(m, 4H), 1.52(s, 6H).; LRMS(ES)m / z511.4(M + +1).
[0327] Synthesis of Compound 21,7-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-2-methyl-5-phenyl-2,5,7-triazaspiro[3.4]octan-6,8-dione
[0328] [Step 1] Synthesis of 3-cyano-3-(phenylamino)fluoroheterocyclobutane-1-carboxylic acid benzyl ester
[0329]
[0330] Aniline (1.961 mL, 21.475 mmol), trimethylsilylcarbonitrile (2.131 g, 21.475 mmol) and benzyl 3-oxoazetidine-1-carboxylate (4.407 g, 21.475 mmol) were dissolved in acetic acid (20 mL) at room temperature, and the resulting solution was stirred at the same temperature for 18 hours. The solvent was removed from the reaction mixture under reduced pressure, and ethyl acetate (10 mL) and hexane (20 mL) were added to the resulting concentrate and stirred to filter out the precipitated solid, wash with hexane, and dry to obtain the title compound (4.700 g, 71.2%) as a white solid.
[0331] [Step 2] Synthesis of 6,8-dioxo-5-phenyl-2,5,7-triazaspiro[3.4]octane-2-carboxylic acid benzyl ester
[0332]
[0333] Benzyl 3-cyano-3-(phenylamino)azetidine-1-carboxylate (4.700 g, 15.292 mmol) and chlorosulfonyl isocyanate (3.246 g, 22.938 mmol) prepared in step 1 were dissolved in dichloromethane (50 mL), and the resulting solution was stirred at 0° C. for 30 minutes and at room temperature for another 18 hours. 1N-hydrochloric acid aqueous solution (10 mL) was poured into the reaction mixture, and the solvent was concentrated under reduced pressure, and then ethanol (30 mL) was added. The resulting mixture was stirred again at 80° C. for 30 minutes, and the solvent was concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane=0 to 50%) and concentrated to obtain the title compound (2.200 g, 40.9%) as a white solid.
[0334] [Step 3] Synthesis of 7-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-6,8-dioxo-5-phenyl-2,5,7-triazaspiro[3.4]octane-2-carboxylic acid benzyl ester
[0335]
[0336] Benzyl 6,8-dioxo-5-phenyl-2,5,7-triazaspiro[3.4]octane-2-carboxylate (0.500 g, 1.423 mmol), 2-(6-(bromomethyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.413 g, 1.423 mmol) and potassium carbonate (0.393 g, 2.846 mmol) prepared in step 2 were dissolved in N,N-dimethylformamide (5 mL) at 80° C., and the resulting solution was stirred at the same temperature for 18 hours, and then the reaction was completed by lowering the temperature to room temperature. The solvent was removed from the reaction mixture under reduced pressure, and water was poured into the resulting concentrate, which was then extracted with dichloromethane. The organic layer was washed with a saturated sodium chloride aqueous solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane = 0 to 50%) and concentrated to afford the title compound (0.600 g, 75.2%) as a white solid.
[0337] [Step 4] Synthesis of 7-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5-phenyl-2,5,7-triazaspiro[3.4]octan-6,8-dione
[0338]
[0339] Benzyl 7-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-6,8-dioxo-5-phenyl-2,5,7-triazaspiro[3.4]octane-2-carboxylate (0.600 g, 1.070 mmol) prepared in step 3 was dissolved in methanol (10 mL) at room temperature, and then 10%-Pd / C (60 mg) was slowly added and stirred at the same temperature for 18 hours in the presence of a hydrogen balloon attached thereto. The reaction mixture was filtered through a celite pad to remove solids therefrom, and then the solvent was removed from the obtained filtrate under reduced pressure, and then the obtained product was used without additional purification treatment (0.450 g, 98.6%, colorless oil).
[0340] [Step 5] Synthesis of Compound 21
[0341]
[0342] 7-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl-5-phenyl-2,5,7-triazaspiro[3.4]octan-6,8-dione (0.150 g, 0.352 mmol) prepared in step 4, formaldehyde (37.00% solution, 0.053 mL, 0.704 mmol) and sodium triacetoxyborohydride (0.149 g, 0.704 mmol) were dissolved in a flask at room temperature. In dichloromethane (10mL), the resulting solution was then stirred for 18 hours at the same temperature. Water was poured into the reaction mixture and extracted with dichloromethane. The organic layer was washed with a saturated sodium chloride aqueous solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified and concentrated by column chromatography (SiO2, 12g cartridge; methanol / dichloromethane = 0 to 10%) to obtain the title compound (0.100g, 64.5%) in the form of a colorless oil.
[0343] 1 H NMR (400MHz, CDCl3) δ9.24 (d, J=2.2Hz, 1H), 8.36 (dd, J=8.2, 2.2Hz, 1H), 7.53~7.42 (m, 6H), 7 .08(s, 0.25H), 6.95(s, 0.5H), 6.82(s, 0.25H), 4.99(s, 2H), 3.80~3.73(m, 4H), 2.31(s, 3H).
[0344] Synthesis of Compound 22, 7-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-2-isopropyl-5-phenyl-2,5,7-triazaspiro[3.4]octan-6,8-dione
[0345]
[0346] 7-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5-phenyl-2,5,7-triazaspiro[3.4]octan-6,8-dione (0.100 g, 0.235 mmol), acetone (0.035 mL, 0.469 mmol) and sodium triacetoxyborohydride (0.099 g, 0.469 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and the resulting solution was stirred at the same temperature for 18 hours. Water was poured into the reaction mixture and extracted with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; methanol / dichloromethane=0 to 10%) and concentrated to obtain the title compound (0.070 g, 63.7%) as a colorless oil.
[0347] 1 H NMR (400MHz, CDCl3) δ9.24 (t, J=1.1Hz, 1H), 8.36 (dd, J=8.2, 2.2Hz, 4H), 7.51~7.39 (m, 6H), 7.08 ( s, 1H), 6.95 (s, 1H), 6.82 (s, 1H), 4.98 (s, 2H), 3.84 (s, 4H), 2.58~2.55 (m, 1H), 0.91~0.87 (m, 6H).
[0348] Synthesis of Compound 23, 2-acetyl-7-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5-phenyl-2,5,7-triazaspiro[3.4]octan-6,8-dione
[0349]
[0350] 7-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5-phenyl-2,5,7-triazaspiro[3.4]octan-6,8-dione (0.124 g, 0.291 mmol), acetyl chloride (0.041 mL, 0.582 mmol) and N,N-diisopropylethylamine (0.101 mL, 0.582 mmol) were dissolved in dichloromethane (5 mL) at room temperature, and the resulting solution was stirred at the same temperature for 18 hours. Water was poured into the reaction mixture and extracted with dichloromethane. The organic layer was washed with a saturated sodium chloride aqueous solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; methanol / dichloromethane = 0 to 10%) and concentrated to afford the title compound (0.100 g, 73.4%) as a colorless oil.
[0351] 1 H NMR (400MHz, CDCl3) δ9.26 (t, J=1.1Hz, 1H), 8.40 (dd, J=8.2, 2.2Hz, 1H), 7.55~7.39 (m, 6H), 7.08 (s, 0. 25H), 6.95(s, 0.5H), 6.82(s, 0.25H), 5.03(s, 2H), 4.62~4.48(m, 2H), 4.42~4.33(m, 2H), 1.85(s, 3H).
[0352] Synthesis of Compound 24, 7-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5-phenyl-5,7-diazaspiro[3.4]octan-6,8-dione
[0353] [Step 1] Synthesis of 1-(phenylamino)cyclobutane-1-carbonitrile
[0354]
[0355] Aniline (0.980 mL, 10.738 mmol), cyclobutanone (0.753 g, 10.738 mmol) and trimethylsilylcarbonitrile (1.065 g, 10.738 mmol) were dissolved in acetic acid (20 mL) at room temperature, and the resulting solution was stirred at the same temperature for 18 hours. The solvent was removed from the reaction mixture under reduced pressure, and water was poured into the resulting concentrate, which was then extracted with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane=0 to 30%) and concentrated to obtain the title compound (1.200 g, 64.9%) as a white solid.
[0356] [Step 2] Synthesis of 5-phenyl-5,7-diazaspiro[3.4]octan-6,8-dione
[0357]
[0358] 1-(Phenylamino)cyclobutane-1-carbonitrile (1.000 g, 5.806 mmol) and chlorosulfonyl isocyanate (0.761 mL, 8.709 mmol) prepared in step 1 were dissolved in dichloromethane (20 mL) at room temperature, and the resulting solution was stirred for 12 hours at the same temperature. Thereafter, 1M HCl (10 mL) was added to the reaction mixture, and the reaction was then completed to remove the solvent. Ethanol (10 ml) was added to the reaction mixture and stirred at 80 ° C for one hour. The solvent was removed from the reaction mixture under reduced pressure, and then ethyl acetate (20 mL) and hexane (10 mL) were added to the resulting concentrate and stirred to filter out the precipitated solid, washed with hexane, and dried to obtain the title compound (0.950 g, 75.7%) as a white solid.
[0359] [Step 3] Synthesis of compound 24
[0360]
[0361] 5-Phenyl-5,7-diazaspiro[3.4]octan-6,8-dione (0.100 g, 0.462 mmol) prepared in step 2 was dissolved in N,N-dimethylformamide (20 mL) at 0°C, and sodium hydride (60.00%, 0.022 g, 0.555 mmol) was added to the resulting solution and stirred at the same temperature for 30 minutes. 2-(6-(bromomethyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.134 g, 0.462 mmol) was added to the reaction mixture and stirred at room temperature for another 2 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with saturated sodium chloride aqueous solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 40 g cartridge; ethyl acetate / hexane = 0 to 50%) and concentrated to afford the title compound (0.130 g, 66.1%) as a yellow oil.
[0362] 1 H NMR (400MHz, CDCl3) δ9.30~9.26 (m, 1H), 8.37 (dd, J=8.2, 2.2Hz, 1H), 7.53~7.43 (m, 4H), 7.33~7.31 (m, 2H), 7.08 ( s, 0.25H), 6.95 (s, 0.5H), 6.82 (s, 0.25H), 5.00 (s, 2H), 2.59 ~ 2.42 (m, 4H), 2.23 ~ 2.04 (m, 2H), 1.69 ~ 1.63 (m, 2H).
[0363] Synthesis of Compound 25, 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(4-(furan-3-yl)phenyl)-5,5-dimethylimidazolidine-2,4-dione
[0364] [Step 1] Synthesis of 2-((4-bromophenyl)amino)-2-methylpropionitrile
[0365]
[0366] 4-Bromoaniline (3.000 g, 17.439 mmol), propan-2-one (1.013 g, 17.439 mmol) and trimethylsilylcarbonitrile (1.730 g, 17.439 mmol) were dissolved in acetic acid (10 mL) at room temperature, and the resulting solution was stirred at the same temperature for 12 hours. The solvent was removed from the reaction mixture under reduced pressure, and ethyl acetate (10 mL) and hexane (20 mL) were added to the resulting concentrate and stirred to filter out the precipitated solid, wash with hexane, and dry to obtain the title compound (2.700 g, 64.7%) as a white solid.
[0367] [Step 2] Synthesis of 1-(4-bromophenyl)-5,5-dimethylimidazolidine-2,4-dione
[0368]
[0369] 2-((4-bromophenyl)amino)-2-methylpropionitrile (2.740 g, 11.459 mmol) prepared in step 1 and chlorosulfonyl isocyanate (1.502 mL, 17.188 mmol) were dissolved in dichloromethane (5 mL) at room temperature, and the resulting solution was stirred at the same temperature for 18 hours. 1M HCl (10 mL) was added to the reaction mixture to concentrate the organic layer, and then ethanol (20 mL) was added and stirred at 80° C. for one hour. Thereafter, the solvent was removed from the reaction mixture under reduced pressure, and then ethyl acetate (20 mL) and hexane (30 mL) were added to the resulting concentrate and stirred to filter out the precipitated solid, wash with hexane, and dry to obtain the desired compound (2.5 g, 77.1%) as a white solid.
[0370] [Step 3] Synthesis of 1-(4-bromophenyl)-3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethylimidazolidine-2,4-dione
[0371]
[0372] 1-(4-Bromophenyl)-5,5-dimethylimidazolidine-2,4-dione (1.000 g, 3.532 mmol), 2-(6-(bromomethyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole (1.025 g, 3.532 mmol) and potassium carbonate (0.976 g, 7.064 mmol) prepared in step 2 were dissolved in N,N-dimethylformamide (30 mL) at 50°C, and the resulting solution was stirred at the same temperature for 12 hours, and then the reaction was completed by lowering the temperature to room temperature. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 40 g cartridge; ethyl acetate / hexane=0 to 50%) and concentrated to obtain the title compound (1.300 g, 74.8%) as a yellow solid.
[0373] [Step 4] Synthesis of compound 25
[0374]
[0375] 1-(4-bromophenyl)-3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethylimidazolidine-2,4-dione (0.150 g, 0.305 mmol) prepared in step 3, furan-3-ylboronic acid (0.051 g, 0.457 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (II, 0.020 g, 0.030 mmol) and cesium carbonate (0.149 g, 0.457 mmol) were mixed in 1,4-dioxane (6 mL) / water (2 mL), and the resulting mixture was irradiated with microwaves, then heated at 100° C. for 20 minutes, and then the reaction was completed by lowering the temperature to room temperature. The solvent was removed from the reaction mixture under reduced pressure, and water was poured into the resulting concentrate, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; methanol / dichloromethane = 0 to 10%) and concentrated to obtain the title compound (0.022 g, 15.1%) in the form of a brown oil.
[0376] 1H NMR (400MHz, CDCl3) δ9.30 (dd, J=2.2, 0.8Hz, 1H), 8.40 (dd, J=8.2, 2.2Hz, 1H), 7.77~7.74 (m, 2H), 7.52~7.49 (m, 2H), 7.35~7.32 (m, 2H), 7.08 (s, 0.25H), 6.95 (s, 0.5H), 6.82 (s, 0.25H), 6.72 (dd, J=3.4, 0.7Hz, 1H), 6.51 (dd, J=3.4, 1.8Hz, 1H), 5.04 (s, 2H), 1.56 (s, 6H).; LRMS (ES) m / z 480.3(M + +1).
[0377] Compound 26, Synthesis of 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethyl-1-(4-(pyridin-4-yl)phenyl)imidazolidine-2,4-dione
[0378]
[0379] 1-(4-Bromophenyl)-3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethylimidazolidine-2,4-dione (0.150 g, 0.305 mmol), pyridin-4-ylboronic acid (0.056 g, 0.457 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II, 0.020 g, 0.030 mmol) and cesium carbonate (0.149 g, 0.457 mmol) were mixed in 1,4-dioxane (6 mL) / water (2 mL), and the resulting mixture was irradiated with microwaves, then heated at 100° C. for 20 minutes, and then the reaction was completed by lowering the temperature to room temperature. The solvent was removed from the reaction mixture under reduced pressure, and water was poured into the resulting concentrate, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; methanol / dichloromethane = 0 to 10%) and concentrated to obtain the title compound (0.015 g, 10.0%) in the form of a brown oil.
[0380] 1H NMR (400MHz, CDCl3) δ9.29 (dd, J=2.2, 0.8Hz, 1H), 8.70 (dd, J=4.5, 1.6Hz, 2H), 8.39 (dd, J=8.2, 2.2Hz, 1H), 7.73~7.71 (m, 2H), 7.52~7.50(m, 3H), 7.47~7.45(m, 2H), 7.08(s, 0.25H), 6.95(s, 0.5H), 6.82(s, 0.25H), 5.04(s, 2H), 1.60(s, 6H).; LRMS(ES) m / z 491.2(M + +1).
[0381] Compound 27, Synthesis of 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethyl-1-(4-(pyridin-3-yl)phenyl)imidazolidine-2,4-dione
[0382]
[0383] 1-(4-Bromophenyl)-3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethylimidazolidine-2,4-dione (0.150 g, 0.305 mmol), pyridin-3-ylboronic acid (0.056 g, 0.457 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II, 0.020 g, 0.030 mmol) and cesium carbonate (0.149 g, 0.457 mmol) were mixed in 1,4-dioxane (6 mL) / water (2 mL), and the resulting mixture was irradiated with microwaves, then heated at 100° C. for 20 minutes, and then the reaction was completed by lowering the temperature to room temperature. The solvent was removed from the reaction mixture under reduced pressure, and water was poured into the resulting concentrate, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; methanol / dichloromethane = 0 to 10%) and concentrated to obtain the title compound (0.030 g, 20.1%) in the form of a brown oil.
[0384] 1H NMR (400MHz, CDCl3) δ9.30~9.29 (m, 1H), 8.87~8.86 (m, 1H), 8.64 (dd, J=4.8, 1.6Hz, 1H), 8.40 (dd, J=8.2, 2.2Hz, 1H), 7.91~7.88 (m, 1H), 7.68~7 .65(m, 2H), 7.52(d, J=8.2Hz, 1H), 7.46~7.38(m, 3H), 7.08(s, 0.25H), 6 .95(s, 0.5H), 6.82(s, 0.25H), 5.04(s, 2H), 1.60(s, 6H).; LRMS(ES)m / z 491.3(M + +1).
[0385] Compound 28, Synthesis of 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(3′-fluoro-[1,1′-biphenyl]-4-yl)-5,5-dimethylimidazolidine-2,4-dione
[0386]
[0387] 1-(4-Bromophenyl)-3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethylimidazolidine-2,4-dione (0.150 g, 0.305 mmol), (3-fluorophenyl)boronic acid (0.064 g, 0.457 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II, 0.020 g, 0.030 mmol) and cesium carbonate (0.149 g, 0.457 mmol) were mixed in 1,4-dioxane (6 mL) / water (2 mL), and the resulting mixture was irradiated with microwaves, then heated at 100° C. for 20 minutes, and then the reaction was completed by lowering the temperature to room temperature. The solvent was removed from the reaction mixture under reduced pressure, and water was poured into the resulting concentrate, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; methanol / dichloromethane = 0 to 10%) and concentrated to obtain the title compound (0.060 g, 38.8%) in the form of a brown oil.
[0388] 1H NMR (400MHz, CDCl3) δ9.31~9.30 (m, 1H), 8.40 (dd, J=8.2, 2.2Hz, 1H), 7.67~7.64 (m, 2H), 7.52 (d, J=8.2Hz, 1H), 7.45~7. 28 (m, 5H), 7.11~7.07 (m, 1H), 7.08 (s, 0.25H), 6.95 (s, 0.5H), 6.82 (s, 0.25H), 5.05 (s, 2H), 1.60 (s, 6H).; LRMS (ES) m / z 508.2(M + +1).
[0389] Compound 29, Synthesis of 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(2′-fluoro-[1,1′-biphenyl]-4-yl)-5,5-dimethylimidazolidine-2,4-dione
[0390]
[0391] 1-(4-Bromophenyl)-3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethylimidazolidine-2,4-dione (0.150 g, 0.305 mmol), (2-fluorophenyl)boronic acid (0.064 g, 0.457 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II, 0.020 g, 0.030 mmol) and cesium carbonate (0.149 g, 0.457 mmol) were mixed in 1,4-dioxane (6 mL) / water (2 mL), and the resulting mixture was irradiated with microwaves, then heated at 100° C. for 20 minutes, and then the reaction was completed by lowering the temperature to room temperature. The solvent was removed from the reaction mixture under reduced pressure, and water was poured into the resulting concentrate, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; methanol / dichloromethane = 0 to 10%) and concentrated to obtain the title compound (0.060 g, 38.8%) in the form of a brown oil.
[0392] 1H NMR (400MHz, CDCl3) δ9.30~9.29 (m, 1H), 8.40 (dd, J=8.2, 2.2Hz, 1H), 7.66~7.63 (m, 2H), 7.52~7.33 (m, 5H), 7.26~7.17(m, 2H), 7.08(s, 0.25H), 6.95(s, 0.5H), 6.82(s, 0.25H), 5.04(s, 2H), 1.60(s, 6H).; LRMS(ES) m / z 508.2(M + +1).
[0393] Compound 30, Synthesis of tert-butyl 4-(3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-1H-indole-1-carboxylate
[0394] [Step 1] Synthesis of tert-butyl 4-((2-cyanopropyl-2-yl)amino)-1H-indole-1-carboxylate
[0395]
[0396] Tert-butyl 4-amino-1H-indole-1-carboxylate (1.680 g, 7.233 mmol), propan-2-one (0.420 g, 7.233 mmol) and trimethylsilylcarbonitrile (0.718 g, 7.233 mmol) were dissolved in acetic acid (30 mL) at room temperature, and the resulting solution was stirred at the same temperature for 18 hours. The solvent was removed from the reaction mixture under reduced pressure, and ethyl acetate (10 mL) and hexane (20 mL) were added to the resulting concentrate and stirred to filter out the precipitated solid, wash with hexane, and dry to obtain the title compound (1.930 g, 89.1%) as a white solid.
[0397] [Step 2] Synthesis of tert-butyl 4-(5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-1H-indole-1-carboxylate
[0398]
[0399] Tert-butyl 4-((2-cyanopropyl-2-yl)amino)-1H-indole-1-carboxylate (1.930 g, 6.447 mmol) and chlorosulfonyl isocyanate (1.369 g, 9.670 mmol) prepared in step 1 were dissolved in dichloromethane (30 mL) at room temperature, and the resulting solution was stirred for 18 hours at the same temperature. 1M HCl (10 mL) was poured into the reaction mixture, and the solvent was concentrated under reduced pressure. Thereafter, the resulting concentrate was dissolved in ethanol (20 mL), and then stirred at 80° C. for one hour. The reaction temperature was lowered to room temperature, and then the solvent was removed under reduced pressure. Then, the reaction mixture was dissolved in THF (20 mL), and then 10% K2CO3 solution (10 mL) was added to adjust the pH to 8, and then di-tert-butyl dicarbonate (2.111 g, 9.670 mmol) was added and stirred for 18 hours. Water was poured into the reaction mixture and extracted with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane = 0 to 30%) and concentrated to obtain the title compound (0.250 g, 11.3%) as a white solid.
[0400] [Step 3] Synthesis of compound 30
[0401]
[0402] 4-(5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-1H-indole-1-carboxylic acid tert-butyl ester (0.200 g, 0.582 mmol) prepared in step 2, 2-(6-(bromomethyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.169 g, 0.582 mmol) and potassium carbonate (0.161 g, 1.165 mmol) were dissolved in N,N-dimethylformamide (10 mL) at 45°C, and the resulting solution was stirred at the same temperature for 18 hours, and then the reaction was completed by lowering the temperature to room temperature. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated sodium chloride aqueous solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO 2 , 12 g cartridge; ethyl acetate / hexane=0 to 50%) and concentrated to afford the title compound (0.110 g, 34.2%) as a white solid.
[0403] 1H NMR (400MHz, CDCl3) 9.33 (d, J=1.6Hz, 1H), 8.38 (dd, J=8.2, 2.2Hz, 1H), 8.25~8.23 (m, 1H), 7.66 (d, J=3.8Hz, 1H), 7.52~7.50 (m, 1H), 7.38 (t, J=8.0Hz, 1H), 7.16 (dd, J=7.6, 0.6Hz, 1H), 7.09 (s, 0.25H), 6.96 (s, 0.5H), 6.83 (s, 0 .25H), 6.56 (dd, J=3.8, 0.5Hz, 1H), 5.06 (s, 2H), 1.67 (s, 9H), 1.53 (s, 6H).
[0404] Compound 31, Synthesis of tert-butyl 4-(3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)indoline-1-carboxylate
[0405] [Step 1] Synthesis of tert-butyl 4-((2-cyanopropan-2-yl)amino)indoline-1-carboxylate
[0406]
[0407] Tert-butyl 4-aminoindoline-1-carboxylate (2.300 g, 9.816 mmol), propan-2-one (0.570 g, 9.816 mmol) and trimethylsilylcarbonitrile (0.974 g, 9.816 mmol) were dissolved in acetic acid (30 mL) at room temperature, and the resulting solution was stirred at the same temperature for 18 hours. The solvent was removed from the reaction mixture under reduced pressure, and ethyl acetate (10 mL) and hexane (20 mL) were added to the resulting concentrate and stirred to filter out the precipitated solid, wash with hexane, and dry to obtain the title compound (2.800 g, 94.6%) as a white solid.
[0408] [Step 2] Synthesis of tert-butyl 4-(5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)indoline-1-carboxylate
[0409]
[0410] Tert-butyl 4-((2-cyanopropyl-2-yl)amino)indoline-1-carboxylate (2.800 g, 9.290 mmol) prepared in step 1, chlorosulfonyl isocyanate (1.972 g, 13.935 mmol) and di-tert-butyl dicarbonate (3.041 g, 13.935 mmol) were dissolved in dichloromethane (30 mL) at room temperature, and the resulting solution was stirred for 18 hours at the same temperature. Water was poured into the reaction mixture and extracted with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane=0 to 30%) and concentrated to obtain the title compound (0.490 g, 15.3%) as a white solid.
[0411] [Step 3] Synthesis of compound 31
[0412]
[0413] Tert-butyl 4-(5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)indoline-1-carboxylate (0.485 g, 1.404 mmol), 2-(6-(bromomethyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole (0.407 g, 1.404 mmol) and potassium carbonate (0.388 g, 2.808 mmol) prepared in step 2 were dissolved in N,N-dimethylformamide (10 mL) at 45°C, and the resulting solution was stirred at the same temperature for 18 hours, and then the reaction was completed by lowering the temperature to room temperature. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated sodium chloride aqueous solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane = 0 to 50%) and concentrated to afford the title compound (0.660 g, 84.8%) as a yellow foamy solid.
[0414] 1 H NMR (400MHz, CDCl3) δ9.28 (dd, J=2.2, 0.7Hz, 1H), 8.40 (dd, J=8.2, 2.2Hz, 1H), 7.95 (br s, 1H), 7.50 (dd, J=8.2, 0.7Hz, 1H), 7.28~7.26 (m, 1H), 7.08 (s, 0.25H), 6.95 (s, 0.5H), 6.82 (s, 0 .25H), 6.85~6.83(m, 1H), 5.02(s, 2H), 4.04~4.00(m, 2H), 3.10~3.00(m, 2H), 1.58~1.54(m, 15H).
[0415] Compound 32, Synthesis of 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(1H-indol-4-yl)-5,5-dimethylimidazolidine-2,4-dione
[0416]
[0417] Tert-butyl 4-(3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-1H-indole-1-carboxylate (0.258 g, 0.467 mmol) and trifluoroacetic acid (0.358 mL, 4.669 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and the resulting solution was stirred at the same temperature for 18 hours. The solvent was removed from the reaction mixture under reduced pressure, and a saturated aqueous sodium bicarbonate solution was poured into the resulting concentrate, followed by extraction with dichloromethane. The organic layer was washed with a saturated aqueous sodium chloride solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting product was used without further purification (0.200 g, 94.7%, gray solid).
[0418] 1 H NMR (400MHz, DMSO-d6) 9.21 (d, J=1.9Hz, 1H), 8.48 (dd, J=8.2, 2.2Hz, 1H), 7.72 (s, 0.25H), 7.69 (d, J=8.2Hz, 1H), 7.59 (s, 0.5H), 7.50 (d, J=8.1Hz, 1H), 7.46 (s, 0.25H), 7.40 (t, J=2.8Hz, 1H), 6.99 (d, J=7.0Hz, 1H), 6.42 (t, J=2.2Hz, 1H), 5.75 (s, 1H), 4.96 (s, 2H), 1.42 (s, 6H).
[0419] Compound 33, Synthesis of 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(dihydroindole-4-yl)-5,5-dimethylimidazolidine-2,4-dione
[0420]
[0421] Tert-butyl 4-(3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)indoline-1-carboxylate (0.670 g, 1.208 mmol) and trifluoroacetic acid (0.925 mL, 12.082 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and the resulting solution was stirred at the same temperature for 18 hours. The solvent was removed from the reaction mixture under reduced pressure, and a saturated aqueous sodium bicarbonate solution was poured into the resulting concentrate, followed by extraction with dichloromethane. The organic layer was washed with a saturated aqueous sodium chloride solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting product was used without further purification (title compound, 0.500 g, 91.1%, yellow foamy solid).
[0422] 1 H NMR (400MHz, CDCl3) δ9.28 (t, J=1.1Hz, 1H), 8.39 (dd, J=8.2, 2.2Hz, 1H), 7.50~7.47 (m, 1H), 7.08 (dd, J=8.1, 7.6Hz, 1H), 7.08 (s, 0.25H), 6.95 (s, 0.5H), 6.82 (s, 0.25H), 6.67 (d, J=7.8Hz, 1H), 6.58~6.55 (m, 1H), 5.04 (s, 2H), 3.62~3.56 (m, 2H), 3.01~2.97 (m, 2H), 1.58 (s, 6H).
[0423] Compound 34, Synthesis of 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethyl-1-(3-nitrophenyl)imidazolidine-2,4-dione
[0424] [Step 1] Synthesis of 2-methyl-2-((3-nitrophenyl)amino)propionitrile
[0425]
[0426] 3-Nitroaniline (3.000 g, 21.719 mmol), propan-2-one (1.261 g, 21.719 mmol) and trimethylsilylcarbonitrile (2.155 g, 21.719 mmol) were dissolved in acetic acid (30 mL) at room temperature, and the resulting solution was stirred at the same temperature for 18 hours. The solvent was removed from the reaction mixture under reduced pressure, and ethyl acetate (10 mL) and hexane (20 mL) were added to the resulting concentrate and stirred to filter out the precipitated solid, wash with hexane, and dry to obtain the title compound (4.000 g, 89.7%) as a yellow solid.
[0427] [Step 2] Synthesis of 5,5-dimethyl-1-(3-nitrophenyl)imidazolidine-2,4-dione
[0428]
[0429] 2-Methyl-2-((3-nitrophenyl)amino)propionitrile (4.000 g, 19.491 mmol) prepared in step 1 and chlorosulfonyl isocyanate (4.138 g, 29.237 mmol) were dissolved in dichloromethane (5 mL) at room temperature, and the resulting solution was stirred at the same temperature for 18 hours. 1M HCl (10 mL) was poured into the reaction mixture, and the solvent was concentrated under reduced pressure. Thereafter, the resulting concentrate was dissolved in ethanol (20 mL), and then stirred at 80° C. for one hour. The precipitated solid was filtered, washed with hexane, and dried to obtain the title compound (4.300 g, 88.5%) as a yellow solid.
[0430] [Step 3] Synthesis of compound 34
[0431]
[0432] 5,5-dimethyl-1-(3-nitrophenyl)imidazolidine-2,4-dione (1.000 g, 4.012 mmol) prepared in step 2, 2-(6-(bromomethyl)pyridin-3-yl)-5-(difluoromethyl)-1,3,4-oxadiazole (1.164 g, 4.012 mmol) and potassium carbonate (1.109 g, 8.025 mmol) were dissolved in N,N-dimethylformamide (20 mL) at 45°C, and the resulting solution was stirred at the same temperature for 18 hours, and then the reaction was completed by lowering the temperature to room temperature. Water was poured into the reaction mixture and extracted with ethyl acetate. The organic layer was washed with a saturated sodium chloride aqueous solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 40 g cartridge; ethyl acetate / hexane = 0 to 50%) and concentrated to afford the title compound (1.400 g, 76.1%) as a foamy white solid.
[0433] 1 H NMR (400MHz, CDCl3) δ9.30 (d, J=1.6Hz, 1H), 8.42 (dd, J=8.2, 2.2Hz, 1H), 8.28~8.25 (m, 2H), 7.76~7.73 (m, 1H), 7 .69~7.65 (m, 1H), 7.53~7.51 (m, 1H), 7.08 (s, 0.25H), 6.95 (s, 0.5H), 6.82 (s, 0.25H), 5.05 (s, 2H), 1.63 (s, 6H).
[0434] Compound 35, Synthesis of 1-(3-aminophenyl)-3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethylimidazolidine-2,4-dione
[0435]
[0436] 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethyl-1-(3-nitrophenyl)imidazolidine-2,4-dione (1.400 g, 3.054 mmol) was dissolved in methanol (30 mL) at room temperature, and then Raney nickel was slowly added and stirred at the same temperature for 12 hours in the presence of a hydrogen balloon connected thereto. The reaction mixture was filtered through a celite pad to remove solids therefrom, and then the solvent was removed from the obtained filtrate under reduced pressure, and then the obtained product was used without additional purification treatment (1.200 g, 91.7%, white solid).
[0437] 1H NMR (400MHz, CDCl3) δ9.30 (d, J=1.7Hz, 1H), 8.40 (dd, J=8.2, 2.2Hz, 1H), 7.50 (d, J=8.2Hz, 1H), 7.23 (t, J=8.0Hz, 1H), 7.08(s, 0.25H), 6.95(s, 0.5H), 6.82(s, 0.25H), 6.73~6.68(m, 2H), 6.62~6.61(m, 1H), 5.02(s, 2H), 3.78(br s, 2H), 1.55 (s, 6H).; LRMS (ES) m / z 429.3 (M + +1).
[0438] Compound 36, Synthesis of N-(3-(3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)phenyl)acetamide
[0439]
[0440] 1-(3-Aminophenyl)-3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethylimidazolidine-2,4-dione (0.140 g, 0.327 mmol), acetic anhydride (0.031 mL, 0.327 mmol) and N,N-diisopropylethylamine (0.114 mL, 0.654 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and the resulting solution was stirred at the same temperature for 18 hours. Water was poured into the reaction mixture and extracted with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane=0 to 50%) and concentrated to obtain the title compound (0.110 g, 71.6%) as a foamy white solid.
[0441] 1H NMR (400MHz, CDCl3) δ9.26 (dd, J=2.1, 0.7Hz, 1H), 8.38 (dd, J=8.2, 2.2Hz, 1H), 8.22 (s, 1H), 7.68 (t, J=1.9Hz, 1H), 7.50 (dd, J=8.2, 0.5Hz, 1H), 7. 25(t, J=8.0Hz, 1H), 7.17~7.14(m, 1H), 7.08(s, 0.25H), 6.95(s, 0.5H), 6 .97~6.95 (m, 1H), 6.82 (s, 0.25H), 5.02 (s, 2H), 1.99 (s, 3H), 1.52 (s, 6H).
[0442] Compound 37, Synthesis of 1-(1-acetylindolin-4-yl)-3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-5,5-dimethylimidazolidine-2,4-dione
[0443]
[0444] 3-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-1-(dihydroindole-4-yl)-5,5-dimethylimidazolidine-2,4-dione (0.100 g, 0.220 mmol), acetic anhydride (0.021 mL, 0.220 mmol) and N,N-diisopropylethylamine (0.077 mL, 0.440 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and the resulting solution was stirred at the same temperature for 18 hours. Water was poured into the reaction mixture and extracted with dichloromethane. The organic layer was washed with a saturated sodium chloride aqueous solution, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting concentrate was purified by column chromatography (SiO2, 12 g cartridge; ethyl acetate / hexane = 0 to 50%) and concentrated to afford the title compound (0.080 g, 73.2%) as a foamy white solid.
[0445] 1H NMR (400MHz, CDCl3) δ9.24~9.23 (m, 1H), 8.37 (dd, J=8.2, 2.2Hz, 1H), 8.27 (d, J=8.1Hz, 1H), 7.49 (dd, J=8.2, 0.6Hz, 1H), 7.29~7.25 (m, 1H), 7.08(s, 1H), 6.95(s, 1H), 6.92(d, J=7.6Hz, 1H), 6.82(s, 1H), 5.00(s , 2H), 4.14~4.07(m, 2H), 3.16~3.14(m, 2H), 2.22(s, 3H), 1.52(s, 6H).
[0446] Protocols for measuring and analyzing the activity of compounds of the invention
[0447] <Experimental Example 1> Identification of HDAC enzyme activity inhibition (in vitro)
[0448] Selective HDAC6 inhibitors are important for their selectivity over HDAC1 inhibition (which is responsible for the side effects), therefore HDAC1 / 6 enzyme selectivity as well as cellular selectivity (HDAC1: histone acetylation / HDAC6: tubulin acetylation) were identified.
[0449] 1. Experimental Methods
[0450] The HDAC enzyme inhibition ability of the test substance was measured by using HDAC1 fluorescent drug discovery assay kit (Enzolifesciences: BML-AK511) and HDAC6 human recombinant (Calbiochem: 382180). For HDAC1 determination, samples were processed at a concentration of 100, 1000 and 10000 nM. For HDAC6 determination, samples were processed at a concentration of 0.1, 1, 10, 100 and 1000 nM. After the above sample treatment, the reaction continued at 37 ° C for 60 minutes, treated with a developer, and reacted at 37 ° C for 30 minutes, and then the fluorescence intensity was measured by using FlexStatin3 (Molecular device) (Ex 390, Em460).
[0451] 2. Experimental results
[0452] The results of exploring the inhibition of HDAC enzyme activity obtained according to the above experimental method are shown in Table 2.
[0453] [Table 2]
[0454]
[0455]
[0456] According to Table 2, it can be confirmed that the 1,3,4-oxadiazole derivative compound according to the present invention shows excellent HDAC1 / 6 enzyme selectivity.
Claims
1. A compound represented by the following chemical formula I or a pharmaceutically acceptable salt thereof: [Chemical Formula I] in, Z1 to Z4 are each independently N or CR0, where R0 is H or halogen; R1 is CX3 or CX2H, where X is halogen; for when for When R4 and R5 are each independently H or C1-C4 alkyl, when for When R4 and R5 are each independently C1-C4 alkyl, Z5 is N-R6 or CH2, R6 is C1-C4 alkyl, -C(=O)-(C1-C4 alkyl), -C(=O)-O-(C1-C4 alkyl) or oxetane; L1 is -(C1-C2 alkylene)-; is phenyl, indole or R2 and R3 are each independently H, halogen, phenyl, furanyl, pyridyl, C1-C4 alkyl substituted or unsubstituted piperidyl, C1-C4 alkyl substituted or unsubstituted tetrahydropyridyl, -C(=O)-O-(C1-C4 alkyl), -C(=O)-(C1-C4 alkyl), -NH-C(=O)-(C1-C4 alkyl), -NO2 or -NH2, At least one H of the above R2 and R3 may be independently substituted by halogen or C1-C4 alkyl; and n and m are each independently 1 or 2.
2. The compound represented by Chemical Formula I according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Z1 and Z2 are each independently N, CH or CF, and Z3 and Z4 are each CH; R1 is CF3 or CF2H; R2 and R3 are each independently H, halogen, halogen-substituted or unsubstituted phenyl, furanyl, pyridyl, C1-C4 alkyl-substituted or unsubstituted piperidinyl, C1-C4 alkyl-substituted or unsubstituted tetrahydropyridyl, -C(=O)-O-(C1-C4 alkyl), -C(=O)-(C1-C4 alkyl), -NH-C(=O)-(C1-C4 alkyl), -NO2 or -NH2.
3. The compound represented by Chemical Formula I according to claim 1 or a pharmaceutically acceptable salt thereof, The compound represented by Chemical Formula I is one selected from the following compounds 1 to 37:
4. A pharmaceutical composition comprising a compound represented by Chemical Formula I according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating a disease mediated by histone deacetylase 6 (HDAC 6), wherein the disease mediated by histone deacetylase 6 is selected from infectious diseases, tumors, endocrine diseases, nutritional and metabolic diseases, mental and behavioral disorders, neurological diseases, eye and eye appendage diseases, respiratory diseases, digestive diseases, skin and subcutaneous tissue diseases, musculoskeletal system and connective tissue diseases or malformations, deformations and chromosomal aberrations.
5. The pharmaceutical composition according to claim 4, The endocrine disease, nutritional and metabolic disease is hepatolenticular degeneration, amyloidosis or diabetes; The mental and behavioral disorders are depression or Rett syndrome; The neurological disease is central nervous system atrophy, neurodegenerative disease, movement disorder, neuropathy, motor neuron disease or central nervous system demyelinating disease; The eye and ocular appendage disease is uveitis; The skin and subcutaneous tissue disease is psoriasis; The musculoskeletal system and connective tissue disease is rheumatoid arthritis, osteoarthritis or systemic lupus erythematosus; The deformity, deformation and chromosomal aberration are autosomal dominant polycystic kidney disease; The infectious disease is a prion disease; The tumor is a benign tumor or a malignant tumor; The respiratory disease is asthma; and The digestive disease is alcoholic liver disease, inflammatory bowel disease, Crohn's disease or ulcerative bowel disease.
6. Use of a compound represented by Chemical Formula I according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same as an active ingredient, in the preparation of a medicament for preventing or treating a disease mediated by histone deacetylase 6 (HDAC 6), wherein the disease mediated by histone deacetylase 6 is selected from infectious diseases, tumors, endocrine diseases, nutritional and metabolic diseases, mental and behavioral disorders, neurological diseases, eye and eye appendage diseases, respiratory diseases, digestive diseases, skin and subcutaneous tissue diseases, musculoskeletal system and connective tissue diseases or malformations, deformations and chromosomal aberrations.
7. The use according to claim 6, The endocrine disease, nutritional and metabolic disease is hepatolenticular degeneration, amyloidosis or diabetes; The mental and behavioral disorders are depression or Rett syndrome; The neurological disease is central nervous system atrophy, neurodegenerative disease, movement disorder, neuropathy, motor neuron disease or central nervous system demyelinating disease; The eye and ocular appendage disease is uveitis; The skin and subcutaneous tissue disease is psoriasis; The musculoskeletal system and connective tissue disease is rheumatoid arthritis, osteoarthritis or systemic lupus erythematosus; The deformity, deformation and chromosomal aberration are autosomal dominant polycystic kidney disease; The infectious disease is a prion disease; The tumor is a benign tumor or a malignant tumor; The respiratory disease is asthma; and The digestive disease is alcoholic liver disease, inflammatory bowel disease, Crohn's disease or ulcerative bowel disease.
